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DNA and siRNA must be packaged for protection prior to transfection in vivo 
when they are administered to humans or other animals.  Dr. A. J. Mixson’s 
laboratory at the University of Maryland, Baltimore Medical School has developed a 
family of branched histidine-lysine (HK) peptides that confer improved transfection 
in mice compared to naked nucleic acid.  The branched polymer denoted H3K4b has 
a superior ability to transfect siRNA in vitro compared to H3K(+G)4b.  H3K(+G)4b, 
made by the addition of two glycines to each of the original H3K4b branches, is 
presumably a more flexible polymer, and it allows for better transfection of plasmid 
DNA than H3K4b.  Biophysical characterization of the HK-DNA and HK-siRNA 
complexes is aimed at understanding how the structures of both peptides affect their 
biological activity.  This characterization was performed using ethidium bromide 
exclusion from nucleic acid, DNase I plasmid degradation, dynamic light scattering, 
 
  
circular dichroism, isothermal titration calorimetry and atomic force microscopy.  
Results from the characterization suggest that H3K4b forms condensed regions of 
packaged plasmid with some repeating accessibility of the DNA, compared to a more 
even coating of plasmid by H3K(+G)4b.  Based on these results a “coating versus 
clumping” model was developed to relate the transfection efficiency of each peptide 
to its binding of plasmid DNA.  A specific model for packaging of siRNA with these 
peptides was not developed, but we believe that characteristics that lead to effective 
transfection of plasmid are not key to siRNA delivery.  A better understanding of 
characteristics important to peptide-nucleic acid complex formation may lead to the 
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My thesis and research is dedicated to anyone who has looked into the night 
sky or at the beauty of the natural world around them and wondered “what all is there 
to know about life?”  Carl Sagan once stated: 
 
“For me it is far better to grasp the universe as it really is than to persist in delusion 
however satisfying and reassuring.” 
 
The pursuit of knowledge will constantly drive researchers to further mankind’s 
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1.1 Biological Information Storage 
 The digital age has produced devices that transfer vast amounts of 
information.  Mankind has created data storage devices, which nature has been 
working on and perfecting for billions of years1; 2; 3.  The density of digital 
information stored per gram of nucleic acids is significantly greater than any storage 
device mankind has created to date4; 5.  Starting with the proposed structure of B-form 
DNA by Watson and Crick6, the rapid evolution of the biological sciences has 
uncovered a wealth of information about the intricacies of nucleic acids as data 
storage molecules.  Once we can completely interpret the genetic code of an 
organism, a comprehensive understanding of its biological information exchange will 
be within reach.   
 Key to the ability of nucleic acids to act as data storage molecules is the 
central dogma of molecular biology7.  The central dogma is essential to the 
propagation of information in an organism because it describes how cellular data 
propagates from DNA to RNA and finally to creation of protein7.  Additions to the 
central dogma include DNA and RNA replication and also RNA reverse transcription 
back to DNA7.  Proteins serve as the major intracellular workhorse, comprising 
everything from biological structures to cellular regulatory agents.  The central 
dogma’s elegant scheme is the foundation for many studies conducted in the 
biological sciences. 
1.2 Nucleic Acids as the Key to Disease Treatment 
Advances in technology and a new understanding of genetics over the past 40 




information storage system8.  The ultimate objective is to understand biological 
information exchange adequately enough to improve quality of life.  As the primary 
roles of nucleic acids and genetics in diseases become better understood, a way to 
correct the disease seems attainable9; 10; 11.  Most diseases are categorized as a 
malfunctioning protein, most typically caused by a defect in gene expression or an 
infectious disease12.  Treatment of diseases such as bacterial infections with 
antibiotics has proven to be extremely effective in many cases, but bacteria develop 
resistance to current antibiotic treatment regimens13; 14 15.  There is no effective 
treatment for many genetic diseases, such as Huntington’s disease16.  In addition there 
are many treatment regimens, especially for diseases like cancer that prove to be 
marginally effective in some cases and highly detrimental to the patient17.  The vast 
amount of information acquired by studying the central dogma and genetics has led to 
advances in our understanding of how diseases occur and allow us the ability to attack 
the main root cause of inherited and acquired disorders8. 
Nucleic acid delivery is one of many promising therapies to deal with these 
disorders.  It has major appeal in possibly providing a permanent replacement or 
regulation of a defective gene so no further treatment need be applied11.  Nucleic acid 
therapy has potential applications in treatment of hereditary, acquired or even 
infectious diseases11.  There exist many ways to deliver a nucleic acid in order to 
effect treatment of a disease.  With such a wide variety of applications and 
therapeutic potential, it is important to characterize what makes the best delivery 
vector for a specific application.  The project I have conducted observed biophysical 




therapeutic uses.  This project’s broader impact on the understanding of peptide’s 
interaction with nucleic acids may have applications to effective methods of disease 
treatment.  Eventually the knowledge gained here can be applied to the creation of 
more efficient methods of nucleic acid therapy. 
1.3 Types of Nucleic Acid Payloads for Delivery 
In the realm of therapeutic applications there are a few classes of nucleic acid 
payloads that can be delivered to effect therapy.  Treatment falls into two major 
categories, gene delivery or RNA interference (RNAi).  Gene delivery involves 
permanent or temporary replacement of a malfunctioning gene causing disease, with a 
functional one.  Plasmids can be utilized as a delivery vehicle for genes18.  Viruses 
have evolved to naturally inject their genetic material into a host cell, and they can 
also be engineered to deliver a therapeutic gene19.  Currently, one of the most 
successful utilizations of gene therapy under development has been treatment of 
Severe Combined Immunodeficiency-X1 (X-linked SCID, also referred to as 
adenosine deaminase (ADA) deficiency), which is genetic disorder that causes 
problems with T and NK lymphocyte production9.  A virus was used to successfully 
deliver a functional copy of the gene that causes this disease.  Despite this success, 
the FDA has no approved gene delivery therapeutics for sale as of 201120. 
The second treatment is through RNAi-mediated repression of over-expressed 
or aberrantly expressed genes.  The major appeal of siRNA therapy compared to 
typical small molecule drugs is the ability to suppress the production of the faulty 
protein causing a disease before its translation.  Plasmids can also be utilized to 




more direct approach is to manufacture and deliver the siRNA used for RNAi 
mediation of protein expression.  The appeal of siRNA as a therapeutic compared to 
typical small molecule approaches is the ability to directly regulate a malfunctioning 
gene causing a disease, which has lead to over 30 clinical trials to date22.  
Unfortunately, the furthest these trials have reached is phase III for an siRNA 
therapeutic targeting age-related macular degeneration23.  Many other treatments are 
still in phase I or II trials and pilot feasibility studies23.  However, the future holds 
potential for treatments of diseases like Alzheimer’s and Huntington’s, in which over 
expression of proteins are the causes of the disease16; 24; 25. 
1.4 Key Characteristics of a Nucleic Acid Delivery Agent 
 Addressing what constitutes a good delivery vector is key to its creation.  A 
myriad of factors that go into consideration of a good delivery vector can be boiled 
down into four critical aspects (Figure 1.1).  First, the gene delivery vector has to 
effectively package and protect the nucleic acid (RNA or DNA) of interest during its 
passage through a host of biological media to its target11.  Without protection, most of 
the nucleic acid will be destroyed before it reaches it target.  Even in the event that 
some of the gene therapy agent does reach its target, without proper packaging and 
condensation, it is unlikely it will be able to enter the cell and be effective26.  Second, 
the release of the therapeutic nucleic acid in the correct location is critical11.  The 
therapeutic agent complex formed with the nucleic acid has to be robust and resilient 
to destruction.  However, it also cannot be so robust as to never be degraded, 
inhibiting release of the nucleic acid to allow binding to its target.  Third, the vector 





Figure 1.1 Nucleic Acid Delivery Agent Requirements.  A comprehensive list of requirements for 
an effective nucleic acid delivery agent, adapted from Lavigne11.  These factors can be boiled 
down into four major aspects.  The two factors that are critical to biochemically characterize are 
packaging and release of nucleic acids.  A focus on creation of nucleic acid delivery agents that 
are more effective at packaging and release of their payload can be obtained through better 
insight into their function. 
this manufacturing process, it would also be positive to have a vector that is easy to 
chemically modify in the event it has to be adapted to a new set of conditions.  The 
final key consideration for a good gene delivery agent is an inherent lack of toxicity 
to the host11; 27.  If the vector is toxic, any chances for advancement to clinical trials 
are marginal, discouraging any future therapeutic use.  Packaging and release are the 
two major characteristics of the four that can be biophysically characterized.  
Characterization of these two attributes of a gene delivery vector can yield a wealth of 




1.5  Viral and Non-Viral Nucleic Acid Delivery Agents 
 In light of these key characteristics for a delivery agent, the most prevalent 
vectors that fit the criteria listed above fall into two major categories, viral and non-
viral11.  Viral vectors are a logical choice as a gene delivery agent due to the inherent 
ability of virus to deliver genetic material to the nucleus8; 11.  Some of the first trials 
with gene therapy were accomplished in the early 1980’s through the 1990’s with 
 
Figure 1.2 Non-viral Transfection Agents. Images of four primary gene delivery vectors used 
currently, adapted from a couple of sources11; 28; 29.  Liposomes form a spherical structure with a 
positively charge surface for where nucleic acids associate.  Poly(amidoamine) (PAMAM) and 
branched HK peptides both have an extensive branched network with an abundance of positive 
charge to associate with nucleic acids.  Gold nanoparticles, which have been made popular by 
Chad Mirkin, rely on functionalizing the surface with nucleic acids. 
virus delivery of recombinant DNA8.  In 2000 the first fully successful clinical 
instance of gene therapy, dealing with treatment of SCID-X1, was accomplished9.  





Figure 1.3 Cellular Fates of a Nucleic Acid Complex. An illustration of the possible fates of a 
packaged nucleic acid upon entry into a cell, adapted from Lavigne 11.  The nucleic acid (green) 
is packaged by a delivery agent and introduced to the cell.  The packaged complex associates 
with the cell membrane where an invagination will form.  This invagination will become an 
endosome containing the complex for cell internalization.  The endosome is approximately 500 
nm in diameter, which is very similar to the size of packaged complexes.  The endosome 
containing a complex will be very densely packed.  Once the endosome enters the cell the 
complex has one of two fates; it can be released or possibly fuse with a lysosome.  If released, the 
nucleic acid has a reasonable probability of being unpackaged and delivered to the nucleus.  If 
fused with a lysosome, the packaged nucleic acid could be degraded.  If degradation does not 
occur then escape from the lysosome will occur and subsequent release to the nucleus. 
setbacks.  These vectors are very costly to make, considering the extensive genetic 
modifications the virus has to undergo to be non-toxic to the host11; 19.  Even after 
modification, there still is a possibility of toxicity by causing an immunogenic 
response in the host10; 11; 27.   




appeal as being easy to make, and they hold the promise to be just as effective as viral 
vectors27.  A few of the most studied and used thus far are liposomes, nanoparticles, 
poly-amidoamine (PAMAM) and modified branched polymers (Figure 1.2)29; 30; 31; 32; 
33.  A general illustration for the fate of a delivery agent-nucleic acid complex is 
shown in Figure 1.3.  The advantages of non-viral vectors include easy manufacturing 
making them significantly more cost effective to produce.  During the manufacturing 
process they also retain great potential for modifications that will allow them to be 
adapted to the unique biological conditions that gene delivery presents11.  Cationic 
lipids or liposomes are among some of the first non-viral agents used in successful 
protection and transfection of DNA34.  Past formulations for liposomes consisted of a 
lipid bilayer shell in which the nucleic acid of interest is encapsulated.  A very 
commonly used formulation today is lipofectamine, which forms a cationic particle 
where nucleic acids bind to the surface to form a delivery complex.  Cationic lipid 
vesicles can stick to cellular surfaces in order to facilitate transfection34. 
Nanoparticles are a relatively new approach made popular by Chad Mirkin29.  
They involve functionalizing the outside of a particle with a dense population of 
nucleic acids such as RNA29.  The thought is that the highly dense population of RNA 
aids in stabilizing the nucleic acids during their delivery through biological media29. 
All of these non-viral vectors have the ability to create condensed particles 
containing nucleic acid that are thought to be well protected during transport through 
the blood stream to its cellular target.  In efforts to further the development of small 
cationic molecules for gene delivery came the creation of small poly(amidoamine) 




created around the 
same time, and 
showed an 
impressive ability 
in transfection of 
DNA, especially 
PAMAM26; 35.  
The complexes 
formed by these 
cationic molecules 
with nucleic acids 
are very different 
from liposome-
nucleic acid 
complexes.  It is 
believed that the 
highly positively 
charged nature of  
Figure 1.4 Release of a Nucleic Acid Delivery Complex by the Proton Sponge Mechanism.  The 
amine cationic polymer accepts protons in the acidic endosome environment.  This leads to a 
highly positively charged delivery complex.  The ATPase pump in the endosomal membrane 
pump more protons into the endosome to maintain the acidic environment.  Chloride counter 
ions flow in to counteract the high positive charge of the complex.  Water also enters the 
endosome to counteract the increase concentration of ions.  This sudden influx of ions and water 
causes destabilization and rupture of the endosome releasing its contents36. 
these molecules leads to association with nucleic acid, forming a small aggregated 




of basic amine groups in these molecules can provide a positively charged and 
extended surface area for binding and complexing with nucleic acids35; 37.  Many of 
these cationic polymer are designed to have a pKa lower than biological pH, which 
leads to a high buffering capacity at near-neutral pH.  The amine groups of these 
molecules can accept a large amount of protons in the endosome and become highly 
positively charged.  A proton pump replaces the protons taken from the endosome by 
the peptide.  The influx of positive charged protons leads to an influx of chloride 
counter ions and also water, causing swelling and destabilization of the endosome36.  
This mechanism is called the proton sponge hypothesis (Figure 1.4)36.  Polypeptides 
have also been developed as potential transfection agents embodying many of the 
same successful aspects possessed by PEI and PAMAM.  In addition to endosomal 
swelling, the polypeptide’s branched nature is also an important characteristic which 
is believed to aid in condensation of plasmid DNA, contributing to their transfection 
ability. 
Despite non-viral vectors’ great potential for effective gene delivery, a serious 
set of difficulties still exists before widespread implementation can occur.  Cationic 
lipids suffer from not being as effective as viral vectors at transfection30.  PEI has 
proven to be effective in delivery of DNA and siRNA26, but it is toxic to cells11.  
Modifications to both vectors have led to decreased toxicity of PEI variants and more 
efficient transfection by liposomes.  However, without further modifications, 
lipsomes and PEI are difficult to consider as the only viable options for delivery 
vectors11; 26.  This leaves us with PAMAM and modified polymers as another set of 




presumably has contributed to their initial success as delivery agents.  They also have 
limited cytotoxcicity in transfection trials accomplished thus far33. 
1.6  The Effectiveness of Polypeptides as Nucleic Acid Delivery Vehicles 
Our collaborator Dr. A. James Mixson and his lab have worked extensively on 
the use of modified branched polymers.  They have demonstrated great initial success 
with transfection and broad possibilities for modification during synthesis33.  The 
credit for conception and success of these peptides goes to Dr. Mixson, and his lab 
has provided the in vivo experiments on the response of luciferase activity to nucleic 
acid delivery. 
These peptides are synthesized from naturally occurring histidine and lysine, 
making them recognizable as a peptide substrate and degradable in serum.  Two of 
 
Figure 1.5 Structure of H3K4b and H3K(+G)4b. A schematic of the two histidine lysine (HK) 
polypeptides, H3K4b and H3K(+G)4b.  They each have a three-lysine core with four branches 
(4b) synthesized off of the three epsilon amino of each lysine and one N-terminal alpha amino 
group.  Each branch is composed of a HHHK (H3K) repeated four times.  Both have an 
approximate charge of +24 at pH 7.5 assuming a histidine side chain pKa of 6.  The charge of the 
peptide can get up to +72 if all the terminal and side chain amines become protonated at low pH.  
The only difference between the peptides is the H3K(+G)4b has two glycines inserted at the start 
and middle of each branched region (circled in red), which may provide added flexibility to each 
branch. 
the peptides they have worked with, designated H3K4b and H3K(+G)4b, are shown 
in Figure 1.5.  These two peptides are characterized by a three-lysine core which has 




The only difference between these two peptides is a pair of glycines inserted at the 
beginning and the middle of each branch in H3K(+G)4b.  Though a relatively small 
alteration in structure, these added glycines provide a significant difference in the 
expression of a transfected luciferase gene and also knockdown of endogenously 
expressed luciferase by siRNA. 
In the first experiment a plasmid containing a gene for luciferase was 
complexed with H3K4b or H3K(+G)4b and transfected into a culture of MDA-MB-
435 cells.  Luciferase activity of the cultures was then measured after 24 hours of 
exposure to the transfection complex.  As seen in Figure 1.6, H3K(+G)4b is a 
significantly more efficient transfection agent for plasmid DNA, as indicated by the 
 
Figure 1.6 Expression and Knockdown of Luciferase Activity by Nucleic Acids Delivered by H3K4b 
and H3K(+G)4b.  All transfection experiments were conducted and data provided by the Mixson 
lab (unpublished results).  Markedly better expression with a luciferase expressing plasmid is 
seen with transfection using H3K(+G)4b rather than H3K4b.  Knockdown of luciferase 
expression is 50% for H3K4b and insignificant for H3K(+G)4b. 
markedly higher expression of luciferase over that of H3K4b.  The H3K4b peptide 
had hardly any ability to transfect of plasmid as indicated by the very low level of 
luciferase expression.  The second experiment was designed to measure the ability of 
each peptide to deliver siRNA.  This time MDA-MB-435 cells that stably expressed 
luciferase were exposed to an H3K4b-siRNA or H3K(+G)4b-siRNA complex in 




experiment demonstrated that RNA delivered by H3K4b inhibits luciferase 
expression by about 50% and therefore is a much better carrier of siRNA than 
H3K(+G)4b, which showed no ability to deliver of siRNA.  These stark differences in 
transfection efficiency for DNA versus siRNA by the two peptides present a classic 
biochemistry question of how a slight structural difference can cause a dramatic 
functional difference. 
1.7  Proposed Characterization of H3K4b and H3K(+G)4b-Nucleic Acid Complexes 
The transfection data obtained by Dr. Mixson prompted us to ask what aspects 
of H3K4b and H3K(+G)4b interaction with siRNA and plasmid DNA cause the 
significant differences observed.  It is clear what factors are desired of an ideal 
nucleic acid delivery vector, however the biochemical mechanisms that make a non-
viral vector work are still poorly understood, therefore we would like to elucidate 
interactions of H3K4b and H3K(+G)4b with nucleic acids that contribute to transport, 
protection, cellular uptake and release.  A clear understanding of these biochemical 
factors contributing to gene delivery agent interaction with nucleic acids can help to 
pave the way for creation of better agents. 
Our objective is to correlate the in vitro data for transfection of each of these 
peptides with ethidium bromide exclusion, DNase I degradation, circular dichroism, 
isothermal titration calorimetry, dynamic light scattering and atomic force 
microscopy characterization to draw conclusions about what structural and 
biochemical interactions are causing these differences in transfection.  We can then 
begin to understand the differences in the interaction of these two peptides with 




acids is discovered then we can hopefully draw conclusions about the biophysical 
control of transfection efficiency.  This should provide a starting point for a list of 
important structural aspects that should be built into a gene delivery vector for 





















H3K4b and H3K(+G)4b are cationic polypeptides used for delivery of nucleic 
acids.  The binding of these two peptides to nucleic acids was assessed through dye 
displacement from siRNA and DNA and also DNase I probing of peptide-complexed 
DNA.  Dye exclusion experiments demonstrate that H3K4b and H3K(+G)4b exclude 
ethidium brominde to different extents as the peptides are added to dye-DNA 
complexes.  The dye exclusion is sensitive to local structure in peptide-DNA 
complexes, which reports on the uniformity with which each peptide coats nucleic 
acid.  Exposure of the peptide-DNA complex to DNase I should reveal if the peptides 
form qualitatively different plasmid complexes.  Exposure of DNA to solvent should 
show how densely packed each peptide is on the DNA and will report on differences 
in protection.  Differences in the coverage of nucleic acid with H3K4b and 
H3K(+G)4b with nucleic acid will shed light on the intricate relationship between the 
structure of these two peptides and how this affects their functions as nucleic acid 
delivery agents. 
2.1  Materials and Methods: 
2.1.1 General Procedures and Materials Used 
Materials Used: 
 Plasmid DNA was purified from E. coli cells using Qiagen Midiprep and 
Maxiprep kits.  The DNA was a pRset derivative called prGCN4.  Thanks goes to Dr. 
Dan Gowetski for allowing me use of his plasmid stock.  DNA concentration was 




All 21 base pair β-gal and VEGF siRNA was provided by Dr. Mixson’s laboratory.  
H3K4b and H3K(+G)4b peptides were synthesized and given to us by Dr. Mixson’s 
laboratory.  Peptides were HPLC purified and provided as a concentrated 1.5 mM 
stock solution.  Concentrations of both H3K4b and H3K(+G)4b peptides were 
checked by UV-visible spectrometer quantitation at a wavelength of 214 nm.  All 
water and buffers used were filtered before use with a Whatman Puradisc 25 mm 
sterile and endotoxin free 0.2 µm PES filter media syringe filter.  DNase I was 
purchased from NEB.  Ethidium bromide, acridine orange, and agarose were 
purchased from Sigma Chemicals. 
Concentrations of peptide and nucleic acid used and the calculation of N/P ratio: 
 The N/P is the ratio of all the possibly charged nitrogen groups on the H3K4b 
and H3K(+G)4b peptides to negatively charged phosphate groups on the DNA.  
There are 20 lysines, 48 histidines and 4 terminal amines on each branch which yield 
a total of 72 possibly charged nitrogens on both H3K4b and H3K(+G)4b peptides.  
For the 3 kb prGCN4 plasmid there are 6000 phosphate groups.  The above values 
were then multiplied by the concentration of each component used to come up with a 
concentration of nitrogen or phosphate groups for each biomolecule.  The 
concentration of nitrogens was then divided by the phosphate concentration to yield 
all N/P ratios presented in this document.  The key ratio to observe in all cases is that 
N/P = 3 is the ratio at which there is 1:1 charge neutralization of peptide to phosphate 
backbone of the DNA at pH 7.5.  The charge of the peptide is estimated to be +24 at 
pH 7.5, which assumes that all of the lysines will be protonated.  It is important to 




pKas will be altered by the surrounding environment.  The assumption that the side 
chain pKas will not be affected by proximity to DNA or the surrounding environment 
may not be accurate, making the peptides’ charge different from our estimation. 
Siliconization: 
 Peptide sticking to tips and cuvettes proved to have a large impact on results.  
Therefore, all reactions conducted with peptide and complex formation used 
siliconized tips and tubes.  All cuvettes also had to be siliconized to prevent sticking 
of peptide and complex to the sides.  The procedure for siliconizing the fluorescence 
and UV-Visible spectrometer cuvettes is in Appendix 1. 
2.1.2  Exclusion of Ethidium Bromide and Acridine Orange from Nucleic Acid 
A Cary Eclipse fluorometer was used for the fluorescent ethidium bromide 
(EtBr) exclusion assessment.  A siliconized 700 µL Hellma fluorescence cuvette was 
used to contain all analyzed solutions.  A slit width of 20 nm was used and the 
samples were excited at a wavelength of 335 nm and fluorescence was observed from 
450-650 nm, with a maximum around 607 nm.  A total sample volume of 500 µL 
experiment consisted of a 1x TEN (10 mM Tris, 1 mM EDTA, 100 mM or 50 mM 
NaCl pH 7.5) buffering solution, 0.5 nM DNA (1.5 µM base pairs plasmid) and 5 µM 
EtBr.  A 25 µL volume of a 10 nM DNA stock solution was used to get 0.5 nM of 
DNA in cuvette.  Aliquots of 4 µL from a 1 µM peptide stock were titrated into the 
cuvette yielding 8 nM additions of H3K4b or H3K(+G)4b.  After a total of 32 nM of 
peptide was added to the DNA, aliquots of 4 µL from a 4 µM peptide stock were 




each aliquot was added, a fluorescence spectrum was taken, and a decrease in 
fluorescence signal was observed with addition of peptide.   
Excitation of fluorescent acridine orange was measured in the same way, 
except that excitation was at 415 nm and emission spectra were obtained from 500-
700 nm.  For siRNA experiments, 71 nM siRNA was used in the 500 µL cuvette to 
yield the same base pair concentration used in the DNA experiments.  All 
fluorescence results are volume corrected by calculating the percent of EtBr-DNA 
fluorescence left after adding in each aliquot of peptide. 
2.1.3  DNase I Degradation of Plasmid 
DNase I was used to probe the protection of plasmid DNA-H3K4b and 
H3K(+G)4b complexes.  All reactions and gels were conducted the same day to 
ensure the most reproducible results.  To accomplish this 400 µL reactions with series 
of different peptide concentrations were prepared with a fixed DNA concentration.  
All reactions contained 1x TEN (10 mM Tris, 1 mM EDTA, 100 mM, pH 7.5) and 1x 
DNase I buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 10 mM CaCl2, pH 7.6) in addition 
to the following DNA and peptide concentrations to yield a series of different charge 
ratios as in Table 2.1.  The N/P describes the ratio of possibly positively charged 
Nitrogens on the peptide (N) to Phosphates on the backbone of the DNA (P). 
N/P 0 0.48 0.96 1.8 3.6 4.8 7.2 9.6 
[DNA] (nM) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
[H3K4b] or 
[H3K(+G)4b] (nM) 
0 20 40 75 150 200 300 400 
Table 2.1 Table of Concentrations Used to Yield each N/P Ratio 
After the appropriate amounts of peptide and DNA were combined, the reaction was 




removed before the DNase I reaction was started to provide a zero time point.  A 
1:1000 dilution of the original DNase I 1,000 unit stock solution was created.  A 50 
µL aliquot of the 1:1000 dilution contains 0.0027 units of DNase I, which was then 
added to each reaction.  One unit is defined as the amount of enzyme which will 
completely degrade 1 µg of pBR322 DNA in 10 minutes at 37 °C in DNase I 
Reaction Buffer (NEB website).  Each reaction mixture was then incubated at 37 oC 
for 2, 5 and 10 minutes at the specified DNase I concentration.  DNase I reactions for 
each N/P ratio tube were staggered 20 seconds apart to allow for a buffer region 
between time points when taking aliquots out of each reaction.  A volume of 80 µL 
was removed at each time point and mixed into 50 µL of quenching solution (stock 
solution comprised of: 1x TEN, 25 mM EDTA, 0.24 mg Proteinase K) to stop the 
reaction immediately.  Table 2.2 shows the start time points for DNase I addition and 
all the time points when an 80 µL aliquot was removed (blue), to provide a sample for 
every N/P ratio at 2, 5 and 10 minutes.  This time course scheme was followed for the 
H3K4b, H3K4(+G)b and DNA control sample in the same exact manner. 
N/P 0.46 .90 1.7 3.4 4.6 6.8 9.1 
DNase I 
Added 
0” 20” 40” 1’ 6’20” 6’40” 7’ 
2’ 2’ 2’20” 2’40” 3’ 8’20” 8’40” 9’ 
5’ 5’ 5’20” 5’40” 6’ 11’20” 11’40” 12’ 
10’ 10’ 10’20” 10’40” 11’ 16’20” 16’40” 17’ 
Table 2.2 Time Course for Incubation of Reaction Mixtures with DNase I 
After all of the time course volumes were dispensed into the quenching 
reaction for each N/P ratio, all samples were allowed to incubate at 37 oC for at least 
15 minutes.  After this incubation period, 150 mM NaCl was added to every sample 
to aid in dissociation of the degraded peptide from the DNA.  One volume of 




reaction, inverted and finger tapped to mix (NOT VORTEXED; as this causes 
shearing of the plasmid) and spun at 6,000 x g for 14 minutes in a tabletop eppendorf 
5415D centrifuge.  It was spun at 6,000 x g because the smaller 600 µL low retention 
tubes tend to break apart at the higher stresses of 16,100 x g.  The aqueous phase was 
then transferred to a fresh 1.5 mL tube (not another low retention tube, as the all the 
peptide is removed at this point).  The remaining phenol:chloroform phase was then 
back extracted with an additional 100 µL of water to recover any remaining DNA.  
This mixture was finger tapped to mix and spun at 6,000 x g for 14 minutes.  This 
aqueous phase was then added to the previously extracted phase and one volume of 
chloroform was added to the combined aqueous phase, mixed by finger tapping, and 
spun at 16,100 x g for 14 minutes.  The aqueous phase was then transferred to a new 
tube.  Two volumes of 4 oC 100% EtOH were then added to all samples, mixed, and 
then allowed to cool in the -80 oC freezer for 10 minutes.  Samples were then spun at 
16,100 xg at 4 oC for at least 20 minutes in a tabletop refrigerated Eppendorf 
centrifuge.  The EtOH was then carefully pipetted off and 200 µL of 70% EtOH was 
added to the pellet (not visible).  The samples were mixed then spun down again at 
16,100 x g at 4 oC for at least 20 minutes.  The EtOH was then again pipetted off and 
the samples were dried in a speed-vac for 15 minutes to remove any remaining EtOH.  
The samples were then dissolved in 10 µL of water with 2 µL of 6 x loading dye 
(2.5% Ficoll-400, 11 mM EDTA, 3.3 mM Tris-HCl, 0.017% SDS, 0.015% 
bromophenol blue, pH 8.0) and warmed for 15 minutes at 37 oC to facilitate 
redissolving.  Samples were then loaded onto a 0.5% agarose gel.  The gel was run at 




of the DNA into the gel (this proved to give cleaner bands).  Once the DNA entered 
the gel at lower voltage, the gel was set to 80 V, 100 mA, (approximately 8 W) for 2 
hours.  The gel was then placed into a dish with enough 1x TBE buffer to cover the 
top of the gel (about 300 mL) and 25 µL of 25 mM EtBr solution was added for 
staining.  Staining proceeded for 15 minutes, and then the staining solution replaced 
with distilled water and the gel was allowed to destain for 10 minutes.  The gel was 
then visualized on a UV transilluminator and a photograph taken with a digital 
camera gel imaging system. 
2.1.4 Image J Quantitation of DNase I Degradation Gel 
 An Image J gel quantitation of the percentage of supercoiled DNA left after 
DNase I exposure was carried out as follows.  All images were adjusted for color and 
contrast in Adobe Photoshop.  Images were then imported into Image J and further 
contrast adjustment was made before the gels were quantitated.  The gel image was 
then background subtracted by using the subtract background option under the 
process tab.  A Box was then drawn around the first lane in the row, encompassing 
the supercoiled, nicked and linear bands.  The first lane with the box drawn around it 
was selected by using the select first lane option under analyze, then gel tabs.  
Subsequent lanes in the row were then selected by moving the box over the next lane 
and then using the select next lane option under the analyze, then gel tabs.  Once all 
lanes were selected in a row, the plot lane option was then used under the analyze, 
then gel tabs.  A plot of all the peaks for each lane is then displayed.  The gel analysis 
routine averages the results over each line within the box, providing the equivalent of 




the volume of the peak for analysis.  After all peaks were isolated, the wand tool was 
used to measure the area of supercoiled, nicked and linear bands for each lane.  The 
supercoiled, nicked and linear areas were added up to get the total area of plasmid 
DNA bands in each lane.  The supercoiled area was then divided by the total area for 
each lane to come up with a percentage of supercoiled DNA left in each lane after 
exposure to DNase I. 
2.2  Results: 
2.2.1  EtBr Exclusion Resulting from H3K4b and H3K(+G)4b Binding of Plasmid 
The Ethidium Brominde (EtBr) exclusion experiments were designed to 
obtain a binding constant for H3K4b and H3K(+G)4b binding to nucleic acid.  We 
also wanted to observe any differences in the ability of both peptides to displace EtBr 
upon binding to nucleic acid and relate it to their transfection efficiency.  Based on 
the in vivo data, we speculated that H3K(+G)4b would coat the DNA more 
completley and exclude more EtBr than H3K4b.  From the fluorescence exclusion 
experiment we were not able to derive a binding constant for either peptide because 
they bind too tightly to plasmid, however, we were able to observe differences in 
EtBr displacement.  Exclusion of EtBr from plasmid DNA with binding of H3K4b 
and H3K(+G)4b demonstrated a drop in fluorescence intensity as a function of 
increasing N/P ratios.  Quenching in fluorescence intensity is primarily due to 
displacement of EtBr from intercalation sites between the base pairs of the plasmid26.  




complex formation.  No interaction was observed between either H3K4b or 
 
Figure 2.1 Exclusion of EtBr bound to DNA through H3K4b and H3K(+G)4b peptide binding.  
EtBr bound DNA was titrated with increasing concentrations of peptide presented as the N/P 
ratio.  All spectra have been corrected for concentration and fluorescence changes due to 
dilution.  In the left panels, the fluorescence intensity is plotted vs. N/P ratio.  A decrease in 
fluorescence is observed as peptide is added.  The error bars are the standard deviation from an 
average of two trials for the 100 mM NaCl and three trials for the 50 mM NaCl EtBr exclusion 
experiments.  The dashed pink line is the EtBr fluorescence alone (without DNA).  Curves for 
H3K4b are presented in blue and those for H3K(+G)4b, in red.  A and B are the experiments for 
two different NaCl concentrations, 100 mM and 50 mM.  At both salt concentrations, H3K4b 
shows a shallower initial drop in fluorescence, but it reaches a greater final extent of EtBr 
exclusion than H3K(+G)4b.  H3K(+G)4b demonstrates a sharper drop in fluorescence at a lower 
N/P ratio and plateaus at its full extent of EtBr exclusion at lower N/P ratios than H3K4b.  The 
graphs to the right present the same data, normalized to the final extent of EtBr excluded, with 
100% being the maximum extent of EtBr exclusion from the plasmid for each peptide.  The 
saturation average is the average of the last four data points from each titration, which yields 
our value for 100% EtBr displacement.  These data clearly demonstrate greater exclusion of 
EtBr upon H3K(+G)4b binding to DNA than H3K4b at lower N/P ratios (0-2) N/P.  This 
indicates that H3K(+G)4b covers more base pairs of DNA at lower peptide ratios than H3K4b. 
H3K(+G)4b and EtBr alone (data not shown), indicating that the mechanism of 
fluorescence decrease is most likely due to exclusion of EtBr, not quenching through 




exclusion of EtBr is representative of peptide-plasmid DNA complex formation26.  A 
saturating concentration of EtBr was used to bind to DNA. 
The overall trend in fluorescence quenching between the two peptides was 
similar, with some differences in ability to exclude EtBr as presented in Figure 2.1.  
The entire fluorescence titration is presented as the fluorescence intensity as a 
function of increasing N/P ratio.  For both peptides most of the fluorescence decrease 
through EtBr exclusion is occurring between 0 and 3 N/P ratio, 3 being the point of 
charge neutralization.  H3K(+G)4b reaches essentially its final extent of EtBr 
exclusion by N/P = 3, and is slightly more effective at excluding a greater amount of 
EtBr at lower peptide concentrations than H3K4b.  H3K4b requires more peptide to 
excluded the same amount of EtBr, but the fluorescence is decreased more at 
saturating H3K4b than at saturating H3K(+G)4b.  Fluorescence never completely 
reaches the level it starts out with before binding to DNA.  This is most likely due to 
residual EtBr still bound to the DNA even after peptide binding.  In the 100 mM 
NaCl experiments, the average percent of EtBr excluded was calculated to be 97% for 
H3K4b and 90% for H3K(+G)4b.  In the 50 mM NaCl experiments, the average 
percent of EtBr excluded was calculated to be 98% for H3K4b and 92% for 
H3K(+G)4b. 
To emphasis H3K(+G)4b’s greater exclusion of EtBr at lower N/P ratios, the 
same data was plotted in terms of the final extent of excluded fluorescence at 
saturating N/P ratios.  The last four points of the fluorescence curve were averaged 




exclusions had reached its full extent.  The following equation was then used to 
obtain the percent of EtBr excluded from the DNA at each N/P ratio: 
F( )I ! F( )Exp
F( )I ! F( )Saturation ! F( )avg( )
*100 =% EtBr Excluded  
Where (F)I is the initial fluorescence and (F)Exp is the experimental fluorescence at 
each N/P ratio.  The percent excluded EtBr graphs are presented to the right of the 
original data in Figure 2.1.  This presentation of the data clearly demonstrates 
H3K(+G)4b’s enhanced ability to exclude EtBr between N/P = 0.5 and 2.  
H3K(+G)4b is suggested to allow more of the positive charges on the peptide to come 
in close contact with the DNA due to the added flexibility afforded by the glycines, 
which causes more EtBr displacement at lower peptide concentrations.  The final 
extent of EtBr displacement occurs at a higher level of fluorescence for H3K(+G)4b 
because of protected sites for EtBr dye that are maintained during binding.  In 
comparison, at lower N/P ratios of H3K4b, plasmid DNA is not coated as effectively, 
leaving exposed regions of plasmid still bound by EtBr.  Once enough H3K4b is 
added, these gaps are bound and more EtBr can be displaced, leading to the greater 
overall decrease in fluorescence observed.  This is the first piece of data to lead to the 
idea for differences in coating for the two peptides. 
In addition to assessing the two peptides binding to plasmid, the EtBr 
exclusion was done at two NaCl concentrations, 100 mM and 50 mM, to observe 
possible electrostatic effects on peptide binding.  Both NaCl concentrations 
demonstrate a similar extent of EtBr exclusion from both H3K4b and H3K(+G)4b 




2.2.2 Sequential vs. Single-Step addition of H3K4b and H3K(+G)4b to Plasmid 
 In vivo nanoplexes are prepared by adding the full amounts of plasmid and 
peptide together needed to form a transfection complex, not by titration.  Thus, it was 
important to observe any differences between sequential titration compared to single-
step addition of the peptide in the EtBr fluorescence exclusion analysis (Figure 2.2).  
An EtBr displacement experiment was conducted in the same manner as presented in 
section 2.2.1.  An experiment was then conducted at the same time, adding in a 1.8 
and 
 
Figure 2.2 Sequential compared to single-step addition of H3K4b and H3K(+G)4b peptides to 
plasmid DNA.  Fluorescence is plotted as the fluorescence intensity of the sample (I) divided by 
the starting fluorescence of EtBr bound to DNA (Io) before peptide was added.  The plotted blue 
and red open circles are the results for the sequential addition of H3K4b and H3K(+G)4b to 
plasmid DNA.  The pink dashed pink line is the EtBr fluorescence alone (without DNA).  The 
green triangles are data for a single-step addition of peptide at 1.8 N/P.  The single step addition 
was followed by a titration of increasing peptide to see if we reach the same level of quenching as 
in the sequential addition.  The grey squares present the same single-step experiment starting off 
with an addition of a 3.6 N/P ratio.  A. H3K4b added to plasmid DNA sequentially shows 
different exclusion for EtBr compared to single-step at N/P ratios of 1.8.  B. H3K(+G)4b added 
sequentially to EtBr bound plasmid shows a similar extent of exclusion compared to single-step 
addition.  The 1.8 N/P ratio shows a deviation from the sequential addition at N/P between 3 and 
5. 
3.6 N/P ratio of peptide to DNA instead of titrating in small aliquots of peptide.  After 
the initial single-step addition of peptide was completed, subsequent aliquots of 
peptide were added as in the titration experiments to observe additional effects on 




EtBr at a given concentration, then the order of peptide addition should not have an 
impact on the levels of fluorescence observed.  We end up observing subtle 
differences in the levels of fluorescence reached with single-step addition followed by 
titration compared to titration alone with H3K4b and H3K(+G)4b.  With H3K4b at 
the 1.8 N/P ratio, exclusion of EtBr occurred to a greater extent than in the sequential 
addition, indicating some variability during complex formation with plasmid.  Whole 
addition of H3K4b presented a similar decrease in fluorescence compared to the 
sequential addition at a 3.6 N/P ratio.  On the other hand, H3K(+G)4b shows EtBr 
exclusion values for the single-step addition of peptide comparable to sequential 
addition.  The only real variation observed is that after more peptide is added to the 
1.8 N/P single-step addition, fluorescence levels off at lower N/P.  The larger 
decrease in fluorescence observed in the EtBr exclusion at N/P = 1.8 of the single-
step addition of H3K4b is most likely due to the peptides inability to completely coat 
the DNA, leaving an open network of DNA for further binding of EtBr.  For 
H3K(+G)4b single-step addition at 1.8 N/P, there is better coverage of the DNA, 
forming a shell that does not allow any further exclusion of EtBr. 
2.2.3 AO bound Plasmid Quenching Via H3K4b and H3K(+G)4b Binding 
A similar experiment to the EtBr exclusion assay was conducted with 
observing exclusion of a different fluorescent dye, Acridine Orange bound to plasmid 
DNA for two major reasons.  The first was to corroborate our findings for the plasmid 
EtBr exclusions experiments. The second was to develop an assay in which we can 
observe exclusion of a fluorescence dye bound to siRNA, which we were not able to 




assess because of the data’s agreement with the results observed for EtBr exclusion 
during peptide binding.  An AO concentration was chosen based on the maximum 
fluorescence intensity we could obtain while bound to plasmid DNA.  Presented in 
Figure 2.3, H3K4b and H3K(+G)4b quenching of fluorescent AO bound to plasmid 
DNA at 100 mM and 50 mM NaCl.  AO proved to be difficult dye to work 
 
Figure 2.3 Fluorescence Decrease of AO bound to DNA through H3K4b and H3K(+G)4b Binding.  
(Left) H3K4b (blue) and H3K(+G)4b’s binding to plasmid DNA was assessed by quenching of 
bound AO fluorescence.  Results proved to be similar to that of the EtBr exclusion assay.  
H3K(+G)4b demonstrates a greater extent of fluorescence decrease at a lower N/P than H3K4b.  
H3K4b quenches more AO fluorescence at saturating N/P ratio.  These results correlate well 
with the EtBr results; however, by themselves are not a good measure of peptide binding.  The 
same data was plotted again in the same manner as the EtBr displacement curve in Figure 2.1.  
The graph to the right present the same data, normalized to the final extent of AO’s decrease in 
fluorescence.  H3K(+G)4b demonstrates a significantly greater decrease in AO fluorescence at 
lower N/P ratios than H3K4b. 
with for two major reasons (which will also be discussed more in section 2.2.4 and 
2.3.6).  One is that both peptides were found to bind AO and cause a decrease in 
fluorescence in the absence of nucleic acid.  This makes it difficult to assess whether 
a decrease in fluorescence is coming from exclusion of the AO from the DNA or 
quenching of the dye from the peptide.  The decrease in fluorescence signal observed 
for the DNA-AO exclusion went below the free AO fluorescence signal.  The other is 
that AO alone fluorescence compared to AO with nucleic acid was not very different.  




association to nucleic acid, however we did not observe this.  H3K4b shows less 
exclusion and subsequent decrease in fluorescence at lower N/P ratios as peptide is 
titrated in.  At saturating N/P ratios of H3K4b, exclusion of AO is greater than that of 
H3K(+G)4b.  For H3K(+G)4b, full exclusion of AO is reached at lower N/P ratios 
and plateaus in fluorescence earlier than H3K4b.  One result that was not observed in 
the EtBr assay that is presented here is a significant reemergence of fluorescence 
upon binding of H3K(+G)4b at higher N/P ratios.  We know at lower concentrations, 
H3K(+G)4b is binding to the DNA which causes fluorescence quenching through 
exclusion of AO.  We believe, as the concentration of H3K(+G)4b increases, more 
peptide binds to the free AO, therefore an interaction of the peptide with the free AO 
must be causing the reemergence of fluorescence observed. 
2.2.4 AO bound siRNA Quenching Via H3K4b and H3K(+G)4b Binding 
Attempts to use EtBr to probe peptide binding to siRNA were unsuccessful 
and yielded very little increase of fluorescence signal EtBr bound siRNA compared to 
free dye.  It became evident after attempts to observe AO exclusion from plasmid and 
siRNA, this would also not be an ideal system to assess siRNA binding to peptide.  
One major problem stems from the fact that AO binding to siRNA provided little 
increase in the fluorescence signal of the bound dye over that of EtBr.  The other is 
that AO fluorescence is not only decreased in the presence of peptide through 




absence of nucleic acid (Figure 2.4 A).  Figure 2.4 B presents the results from the 
 
Figure 2.4 Fluorescence Decrease of AO in the Absence and Presence of siRNA.  A. There is a 
Decrease in AO fluorescence through binding of H3K4b and H3K(+G)4b.  B. A Fluorescence 
Decrease is observed for AO bound to siRNA through H3K4b and H3K(+G)4b Binding.  In 
panel A, Both H3K4b (blue) and H3K(+G)4b show a strong ability to quench peptide in the 
absence of nucleic acid.  The concentrations of peptide used here are in the same range as used 
for siRNA experiments.  This suggests a strong interaction between both of these peptides and 
the AO dye.  This makes analysis of peptide binding to nucleic acid with AO difficult.  In panel 
B, Decreasing in AO fluorescence appears to be greater for H3K4b binding to siRNA than that 
of H3K(+G)4b.  However, there is a large error for the two trials of H3K(+G)4b fluorescence 
decrease conducted.  Excluding the second trial for H3K(+G)4b, results for both peptides 
binding to siRNA are similar.  The fact that both peptides bind and possibly quench AO 
themselves makes this assay a problematic method for assessing peptide binding to siRNA. 
exclusion of AO from siRNA from H3K4b and H3K(+G)4b binding.  A similar 
degree of AO exclusion and fluorescence decrease is observed for the two trials of 
H3K4b and one trial of H3K(+G)4b binding siRNA.  This assessment is made 
complicated by the fact one trial for the H3K(+G)4b peptide demonstrates much less 
of a decrease in fluorescence than the other.  The resulting fluorescence decrease 
during addition of H3K4b and H3K(+G)4b to AO-siRNA prove to be inconclusive in 
distinguishing differences between peptide binding.  There is a definitive interaction 
of H3K4b and H3K(+G)4b with siRNA but extracting real differences between their 




2.2.5 Peptide Protection of Plasmid from DNase I 
 The EtBr exclusion results were the first indication that H3K(+G)4b coats 
plasmid DNA more completley than H3K4b.  This motivated a DNase I assay to 
 
Figure 2.5 DNase I degradation of Plasmid in complex with H3K4b and H3K(+G)4b.  EtBr stained 
0.5% Agarose Gels of H3K4b (A) and H3K(+G)4b (B) peptide bound plasmid DNA complex 
with varying peptide concentrations.  Complexes were exposed to DNase I for 0, 2, 5 and 10 
minutes as illustrated by the triangle gradient.  Lanes are labeled by their corresponding N/P 
ratio, with increasing concentration of peptide going from lanes left to right, with the furthest 
left containing DNA alone.  Disappearance of the supercoiled band (S) as it gets converted into 
nicked and linear DNA (N L) indicates the Peptide-DNA complex susceptibility to degradation.  
A. H3K4b complex formation with DNA demonstrating lessened protection of the DNA.  
Protection of the DNA with H3K4b appears to peak around a 4.8 N/P ratio of peptide to DNA.  
At ratios below 4.8 there is poor protection of supercoiled plasmid from DNase I after 2 minutes 
of incubation.  Above a 4.8 N/P ratio there also appears to be some loss in yield or protection of 
the DNA afforded by higher concentrations of H3K4b.  B. H3K(+G)4b complex formation with 
DNA demonstrates much better protection of DNA.  After a 1.8 N/P ratio is reached, there is 
almost complete retention of the supercoiled DNA, even after 10 minutes of DNase I exposure. 
assess if H3K(+G)4b protected plasmid DNA better than H3K4b.  Conducting this 




EtBr displacement assay gives us a direct comparison between the extent of 
protection and the amount of EtBr displaced. 
Figure 2.5 presents H3K4b’s and H3K(+G)4b’s ability to coat and protect 
plasmid DNA.  Plasmid DNA was incubated in the presence of 20 nM-400 nM 
peptide as in Table 2.1 of the Materials and Methods.  These concentrations yielded 
N/P ratios from 1/6 of the plasmid covered up to 3 times plasmid coverage.  The 
ratios tested allowed us to determine at what ratio of peptide the plasmid showed 
optimal protection.  At much higher ratios of H3K4b, greater than a 3 N/P ratio, (1:1 
charge ratio) the possibility exists for formation of positively overcharged particle 
due to aggregation, which may explain the loss in recovery of the DNA at high N/P 
for H3K4b.  The peptide-DNA complex was allowed to form for 45 minutes and was 
then incubated with DNase I for 0, 2, 5 and 10 minutes to observe the accessibility of 
the DNA.  The bands in the agarose gel show plasmid DNA after phenol extraction to 
remove all peptide.  DNA alone (not in complex with peptide) is the 0 N/P, which 
shows that the plasmid is initially found largely as supercoiled (lowest band) with 
some nicked DNA (upper band).  The first lane of each N/P ratio set with actual 
peptide in it (0.48-9.6), is of DNA that has been incubated with peptide, then 
extracted without ever coming in contact with DNase I.  This was an important 
control lane because it shows that DNA can be recovered from a complex with either 
peptide.  It also verifies that the peptide itself does not cause degradation of the 
plasmid, and the only conversion of supercoiled to nicked DNA is coming from 
DNase I.  Plasmid DNA recovered from a peptide complex without DNase I 




control lanes.  DNA at the 0 N/P ratio after 10 minutes of DNase I incubation 
demonstrates significant conversion of 
 
Figure 2.6 Fraction of Supercoiled DNA Left After Incubation with DNase I.  The fraction of 
supercoiled DNA that remains at each N/P ratio for H3K4b (A) and H3K(+G)4b (B) is plotted 
for 0, 2, 5 and 10 minutes of DNase I incubation.  The no peptide control is presented in red.  N/P 
ratios below a 1:1 charge ratio are plotted in a blue color and ratios above a 1:1 charge ratio are 
plotted in green.  A. H3K4b’s protection of supercoiled plasmid DNA peaks at a 4.8 N/P ratio.  
Ratios above and below this show a significant decrease in the percentage of supercoiled DNA 
due to increased accessibility of the plasmid DNA cause by this peptide.  B. H3K(+G)4b’s 
protection of supercoiled DNA starts to show enhancement over that of naked plasmid at a 1.8 
N/P ratio.  Above the 1.8 ratio, there appears to be complete protection of supercoiled plasmid by 
H3K(+G)4b. 
supercoiled plasmid into nicked and linear.  The objective was to use enough DNase I 
degrade supercoiled into nicked DNA, but not enough to completely destroy the 
plasmid.  A single DNase I cleavage event on the plasmid DNA causes a conversion 
of supercoiled to nicked DNA, resulting in a very sensitive assay for the completeness 
of peptide protection of DNA.   
 Both peptides do provide protection of the DNA, however, at varying degrees 
with different N/P ratios.  Figure 2.6 shows the fraction of supercoiled plasmid DNA 
remaining due to peptide protection by H3K4b and H3K(+G)4b, obtained by Image J 
analysis from Figure 2.5.  The fraction of supercoiled, nicked and linear population of 
plasmid DNA were determined by measuring the integrated volume intensity of each 




presented in Figure 2.7.  As seen in Figure 2.5, the 10 minute lane for 
 
Figure 2.7 Example of the Area of a Peak for the Image J analysis of the DNase I Degradation Gel.  
The area of the peak presented in the top panel is for the nicked, linear and supercoiled gel band 
for a 1.8 N/P ratio at 2 minutes of DNase I incubation and for the bottom panel, the nicked and 
linear gel band of the 0.96 N/P ratio of H3K4b at 10 minutes of DNase I incubation.  There is a 
baseline for the background in the gel that is not included in the peak area measurement for 
each band.  A line is drawn under every peak to eliminate the background.  In the top panel 
there is a peak for the nicked, linear and supercoiled DNA.  In the bottom panel a second peak 
would normally be observed for the supercoiled DNA band, however for this sample, all plasmid 
DNA was converted to nicked and linear.  Therefore we observe no peak for the supercoiled 
DNA. 
0.96 N/P ratio for H3K4b shows only a population for nicked and linear DNA and no 




only a peak for the nicked and linear DNA and not the supercoiled, therefore lanes 
like this one had 0% supercoiled DNA.  Charge neutralization of the peptide-DNA 
complex occurs around a 3 N/P ratio.  As shown in by Figure 2.6, ratios of H3K4b up 
to 3.6 all allow a significant percent conversion of the supercoiled population into 
nicked and linear plasmid.  Conversion of the plasmid DNA into nicked DNA is 
apparent even after 2 minutes of incubation with DNase I at the lowest ratios of 
peptide, which is an indication of very poor protection at low concentrations of 
H3K4.  At lower H3K4b concentrations, protection of the plasmid DNA is very 
similar to that of naked DNA.  Optimal coating of DNA appears to occur around a 4.8 
ratio of peptide to plasmid.  Above a 3.6 N/P ratio, there is a clear decrease in the 
amount of DNA present in the gel, indicating incomplete recovery of the plasmid 
from H3K4b.  It is difficult to say with certainty because of the incomplete recovery 
of plasmid, but protection of H3K4b appears to peak at an optimal N/P ratio.  Below 
this ratio, there is insufficient coating within the complex to protect the DNA from 
DNase I.  Above this optimal ratio, loss in DNA recovery could be attributed to 
excessive aggregation of the peptide with plasmid.  At higher concentrations, the 
peptide may interact with itself in a manner that causes formation of very tight 
aggregates to occur which makes recovery of the DNA more difficult.  The 
aggregates formed by H3K4b could very well be attributed to the peptides less 
flexible structure.  Overall, coating of DNA with H3K4b more incomplete at 
increasing concentrations than that of H3K(+G)4b. 
H3K(+G)4b demonstrates a better ability to coat with increasing HK:DNA 




for H3K4b.  At low HK:DNA ratios (0.48 and 0.96), there is a limited amount of 
protection due to coating by H3K(+G)4b.  This is expected since full charge 
neutralization has not been attained at these ratios.  These are the only ratios at which 
we see accessibility of DNase I to plasmid DNA protected by H3K(+G)4b.  However, 
at a 1.8 N/P ratio (a little over half charge neutralization of plasmid) there is complete 
protection of the DNA over the full 10 minutes of DNase I exposure.  Ratios above 
N/P of 1.8 all show a similar level of protection for plasmid.  Between a ratio of 3.6 
and 4.8, there is slightly better protection of the supercoiled plasmid from conversion 
to nicked and linear DNA, demonstrating superior protection of plasmid DNA 
compared to H3K4b.  H3K(+G)4b completely protects the DNA at a much lower 
HK:DNA ratio.  Once protected, there is very little to no degradation observed for the 
plasmid. 
2.3 Discussion: 
2.3.1 Comparison of H3K4b and H3K(+G)4b Protection to other Delivery Agents 
A host of gene and siRNA delivery agents exist that function to protect and 
deliver nucleic acids to their cellular targets.  Assessment of a gene delivery peptide’s 
ability to coat a nucleic acid is of primary importance.  Without the packaging and 
protection afforded by the peptide, delivery of siRNA or plasmid for RNA 
interference or gene expression would be extremely inefficient due to rapid 
degradation11; 38.  Assays, either utilizing RNases or DNases to degrade RNA or DNA 
have proven very effective at probing the protection of nucleic acids formed with 




cleavage.  Plasmid was combined with nanoparticles and a nuclease was added to 
probe for protection39.  DNA was isolated from the nanoparticles and then run on a 
gel39.  The results demonstrated complete recovery of the supercoiled, linear and 
nicked plasmid in the same ratios as seen with the undigested DNA, which was 
almost identical to the results presented for H3K(+G)4bs complete protection of 
plasmid39.  Similar experiments have also been conducted for protection of siRNA 
with PEI.  PEI-siRNA complex demonstrates complete protection of the siRNA even 
at up to 2 hours of exposure to RNase A40.  Protection assays for siRNA present 
simple results that report on preservation or degradation of nucleic acid but are not 
sensitive to nucleic acid topology40; 41.  These assays form a good foundation for 
assessment of protection. 
2.3.2 Comparison of siRNA and Plasmid DNA Protection Assays 
The size difference of plasmid DNA and siRNA present important 
considerations to the assessment of H3K4b and H3K(+G)4b-nucleic acid complex 
formation.  As a moderate sized nucleic acid, plasmid DNA has distinctive 
topological attributes in which it can assume supercoiled, nicked and linear forms.  It 
will also take many (~300) peptides to completely coat and package a single 3 kb 
plasmid molecule.  Cleavage of DNA into different topological states make this assay 
more sensitive than its siRNA counterpart.  Nicking of DNA indicates only damage to 
one strand of DNA has occurred while linearization of the DNA indicates both 
strands have been cut.  H3K4b and H3K(+G)4b demonstrates a different ability to 
coat DNA based on exposure to DNase I.  In order for protection of the DNA from 




of DNase I through coverage of the plasmid.  DNase I needs at least 10 base pairs of 
surface area to effectively and completely cut DNA42.  This presents the result that 
H3K(+G)4b leaves sections of DNA less than 10 bp in size exposed, while H3K4b is 
leaving segments 10 bp or larger exposed.  This would suggest that delivery agents 
coating does not have to be absolute in coverage of the DNA, just enough to exclude 
access of degradative elements.  Observing the transition of supercoiled DNA to 
nicked and linear provides more information about the assessment of the peptides 
flexibility and coating ability.  This is in contrast to siRNA, in which a very small 21 
bp nucleic acid will have very little unique topology to probe in binding of an 
individual siRNA molecule.  A single 21 bp siRNA needs far fewer peptides (about 
2) to coat and package.  The assessment becomes whether siRNA is either packaged 
and protected or not properly packaged and exposed to degradation. 
2.3.3 EtBr Exclusion via H3K4b and H3K(+G)4b in Light of DNase I Degradation 
Results 
 The observations that H3K4b excludes more dye at saturating concentrations 
than H3K(+G)4b, yet H3K(+G)4b protects the plasmid DNA better than the H3K4b 
provide an interesting contrast.  One might expect instead that the peptide that coats 
nucleic acid the best will also exclude more dye.  The experiments were conducted at 
several N/P ratios chosen to cover the range that produced the full range of binding 
based on the EtBr exclusion experiments.  The H3K(+G)4b peptide has demonstrated 
a trend of reaching the final extent of dye exclusion yielding a greater decrease in 
fluorescence at low N/P ratios in the EtBr and AO fluorescence exclusion 





Figure 2.8 Proposed mechanisms of H3K4b and H3K(+G)4b EtBr plasmid exclusion and plasmid 
protection from DNase I Degradation.  A. H3K4b and H3K(+G)4b displace EtBr from plasmid 
DNA.  H3K4b does not coat the plasmid DNA as effectively leading to less initial exclusion of 
EtBr than for H3K4b.  Upon addition of saturating concentrations of H3k4b, gaps where EtBr 
was still bound are filled in by peptide, excluding more EtBr than H3K(+G)4b at saturating 
concentrations.  Due to H3K(+G)4bs decreased steric bulk, during binding it traps packets of 
EtBr still bound to DNA.  Upon addition of saturating concentrations of H3K(+G)4b there is less 
exclusion of EtBr because of these EtBr pockets trapped by peptide.  This leads to less overall 
exclusion of EtBr for H3K(+G)4b.  B. DNase I plasmid degradation of H3K4b and H3K(+G)4b 
protected DNA complexes.  H3K4b coats plasmid more unevenly, leaving exposed regions of 
plasmid for DNase I accessibility and degradation.  H3K(+G)4b coats plasmid more evenly and 
provides better protection, limiting the accessibility of DNase I to the plasmid.  The overall result 
is more degradation of H3K4b protected plasmid compared to the superior protection of plasmid 




a 1:1 charge to charge ratio of peptide:plasmid DNA.  In both the EtBr exclusion and 
DNase I degradation experiments, this denotes an important ratio where we see the 
significant differences in binding of the two peptides.  At this ratio, EtBr exclusion 
from H3K(+G)4b reaches its full extent and H3K(+G)4b fully protects plasmid DNA 
from DNase I.  H3K4b is believed to coat the plasmid less evenly, resulting in gaps in 
the DNA between coated regions at lower peptide concentrations, which will still 
contain plasmid bound EtBr.  Condensation will exclude more EtBr at higher N/P 
ratios, resulting in an overall greater quenching of fluorescence for H3K4b.  
H3K(+G)4b results demonstrate better protection of the DNA and more efficient 
transfection, however, how does this result in less exclusion of EtBr?  The only 
plausible explanation is the presence of some EtBr left bound even after H3K(+G)4b 
binding to plasmid.  It has been previously demonstrated that a nucleic acid-dye-
binding agent complex may aggregate before all EtBr is excluded from a complex43.  
Two possible factors contributing to H3K(+G)4b yielding higher end point 
fluorescence are protected pockets of EtBr trapped in the DNA during peptide 
binding and small gaps remain after complete assembly, which allow EtBr association 
with DNA.  It has been demonstrated that H3K(+G)4b coats DNA much better at 
lower N:P ratios, indicating that rapid coating of the plasmid by this peptide can lead 
to some trapped EtBr molecules in the DNA.  In addition coating for this peptide is 
superior, but may not be complete. 
Figure 2.8 illustrates a proposed mechanism for EtBr exclusion of plasmid 
during the peptide titration of EtBr bound plasmid and DNase I degradation of 




EtBr by H3K(+G)4b at N:P ratios below 3.6 are most likely due to the flexibility 
afforded by the glycines in the branched regions of this peptide.  This allows for 
better coating of plasmid DNA around a 3.6 ratio and in turn, more EtBr exclusion.  
At higher N/P ratios, H3K4b is most likely excluding more EtBr because the larger 
initial gaps in coating are filled in with more H3K4b and exclude more EtBr at the 
end. 
2.3.4 Delivery Agent Flexibility and its Relation to Nucleic acid Coating 
 The effectiveness of a delivery agent will be strongly linked to the molecule’s 
structure and the complex formed with the nucleic acid11; 44.  In turn, what determines 
the type of interaction formed in a complex between plasmid and a peptide is the 
charge and flexibility of the peptide35.  Both H3K4b and H3K(+G)4b have the same 
positive charge at pH 7.5, but very slight structural differences due to the added 
glycines in the H3K(+G)4b.  Based on this subtle structural difference, Figure 2.5 
demonstrates the very different abilities of H3K4b and H3K(+G)4b to coat plasmid 
DNA.  H3K(+G)4b should have more backbone rotation and less steric hindrance in 
each branch of the peptide due to the added glycines.  The thought is, with added 
flexibility would come better coating and protection of the plasmid, which is 
demonstrated by DNase I protection.  The idea that flexibility of a delivery polymer 
has an impact on coating and transfection ability is not a new concept.  The sensitivity 
of a DNase I based assay to probe coating of λ-DNA has been observed.  One study 
has tested the effect of taking a series of short positively charged lysine peptides 
(which strongly associate with DNAs negatively charged backbone) and added a 




creates a branched polymer delivery agent similar to H3K4b and H3K(+G)4b.  The 
resulting assay, which compares the short lysine peptide with and without the 
scaffolding structure, clearly demonstrates superior protection of λ-DNA with the 
scaffolding45.  This strongly indicates that branching is essential for effective coating 
and protection of the nucleic acid.  However, how does flexibility fit into this 
assessment? 
It has been demonstrated that PAMAM dendrimers have very different 
transfection of plasmid based on how degraded the polymer is35.  Creation of a 
polymer that has fewer branches is accomplished by heat degradation35.  The 
reduction in the density of branching caused by degradation yields a greater flexibility 
of the PAMAM molecule35.  The flexibility of the degraded PAMAM is what’s 
believed to contribute to the enhanced transfection efficiency of plasmid by the 
polymer35.  Another important aspect of this study presents non-degraded PAMAM 
molecules as being more prone to aggregation due to the very dense branching of the 
PAMAM35.  This is most likely due to entanglement and interactions between the 
dense branch regions that cause aggregation.  In contrast to the presumably more 
flexible H3K(+G)4b, H3K4b also presented a poor ability to coat and protect plasmid 
DNA from DNase I.  It is believed that H3K4b cannot coat DNA as well because not 
all of the lysines are interacting with it.  This is most likely due to the slightly greater 
rigidity of the branches of H3K4b, which form localized aggregates of peptide and 
DNA clumps.  These differences in structural interactions observed for H3K4b 
compared to H3K(+G)4b is in good agreement with those observed for difference 




2.3.5 Considerations of the Formation Mechanism of H3K4b and H3K(+G) Nucleic 
Acid Particles Guided by the Order of Addition 
 As demonstrated in Figure 2.2 above, there are some important differences to 
be noted between titrating peptide to nucleic acid compared to mixing all at once.  
This comparison is key because in-vivo transfection of these complexes is 
accomplished by mixing the complex all at once, not added in a sequential manner to 
reach the final N/P ratio.  For the fluorescence experiments it was key to do a titration 
to make an observation about how the complex formed starting from low N/P ratios 
going to saturating concentrations.  For the H3K(+G)4b peptide results for sequential 
compared to single-step addition look similar.  The one deviation from the sequential 
EtBr displacement is after adding more peptide starting from a 1.8 N/P ratio there is a 
plateau in the amount of EtBr displaced.  However, H3K4b presents more significant 
differences between sequential addition and combination of the corresponding N/P 
ratio.  When starting at a 1.8 N/P ratio and adding in more peptide from that point, the 
fluorescence reached a lower level than the sequential addition indicating a 
continuing exclusion of EtBr.  The fluorescence starting at the 3.6 ratio shows a 
similar level of fluorescence.  Continued addition of peptide from the 3.6 ratio 
demonstrated that full extent of exclusion might have been reached earlier.  These 
results suggest that H3K4b’s less effective coating may be causing variability in EtBr 
excluded because there is no set pattern for binding to plasmid DNA.  Since the order 
of addition may matter, the important consideration from these experiments is the 
equilibrium of the formed peptide-nucleic acid complex.  Demonstrating that order of 




be conducted on relating transfection efficiency to the order of delivery agent 
addition. 
2.3.6 Complexities and Complications of AO results 
Overall the AO data corroborated the results we observed for EtBr exclusion 
in the plasmid experiments.  H3K4b excludes more AO at saturating concentrations, 
while H3K(+G)4b reaches its final extent of AO exclusion at lower N/P ratios.  
However, there are some important considerations to keep in mind when assessing 
this data.  AO fluorescence has proven to be very sensitive to a multitude of factors, 
which include solvent salt concentration, the amount of AO dye used, the ratio of dye 
to nucleic acid and small molecule effects46; 47; 48.  The AO dye has been shown to 
form a dimeric complex, which can occur at lower concentrations of AO in the 
presence of salt, affecting fluorescence of the dye at 530 nm48.  Nucleic acid 
concentration can affect AO dimer formation and fluorescence.  At higher nucleic 
acid to dye ratio, intercalation of the dye can prevent the dimer from forming, 
yielding an optimal fluorescence of AO47.  In experiments conducted with AO bound 
to plasmid and siRNA, a large increase in fluorescence was expected over that of the 
AO alone.  The sensitivity of AO dimer formation in the presence of nucleic acid 
could explain why what we actually observed was only a modest increase in the 
bound AO fluorescence signal.  Further optimization of the ratio of nucleic acid to 
AO proved ineffective at yielding a significant increase in AO-nucleic acid 
fluorescence over AO alone.  This made analysis of the AO results more difficult 




signal went below the AO alone fluorescence.  This indicated an interaction of the 
peptide, not only with nucleic acid, but also the AO. 
Quenching of AO was also a concern because of the possible peptide 
interaction with AO.  As seen in Figure 2.4 in section 2.2.4, both peptides interact 
with AO in the absence of nucleic acid and cause fluorescence quenching.  The 
H3K(+G)4b peptide shows greater quenching of the AO at lower N/P ratio than 
H3K4b.  Molecules like caffeine and Bovine Serum Albumin (BSA) have also been 
shown to complex with AO and in the case of caffeine have an effect on AO 
fluorescence46; 48.  Above saturating concentrations of peptide for the nucleic acid, 
there may be an abundance of interaction of the peptide with the AO.  H3K(+G)4b 
may be providing a favorable interaction with AO which promotes an enhancement of 
fluorescence.  Since neither of our peptides proved a conjugated ring system, this 
possibility might be unlikely.  Another potential explanation of enhanced AO 
fluorescence may come from alterations in the plasmid DNA structure during peptide 
binding49; 50.  Delivery agents, such as PEI have been proven to cause structural 
changes in DNA topology upon binding50.  These structural changes in DNA upon 
peptide binding may cause an enhancement of AO fluorescence49.  Since we only see 
this phenomena in the H3K(+G)4b binding and not the H3K4b, this could be a 
powerful tool in assessment of H3K(+G)4bs possible effects on DNA topology. 
The above factors were a big concern in assessing this data because not only 
was exclusion of the dye being observed, but a possible binding and quenching 
interaction between the peptide and dye.  This made the AO experiments more 




also be attributed to H3K4b and H3K(+G)4b quenching AO fluorescence.  The 
resulting binding equilibrium between AO, DNA and peptide would have made 
judging true binding of peptide to nucleic acid in this system very difficult.  For any 
future experiments assessing the binding of a packaging peptide to nucleic acid using 
exclusion of a dye, careful consideration will have to be given to the type of dye used 




3. Chapter 3:  Circular Dichroism and Thermodynamic 

















The structures of H3K4b-DNA and H3K(+G)4b-DNA complexes were 
assessed by Circular Dichroism (CD) and Isothermal Titration Calorimetry (ITC) to 
test whether identifiable biophysical characteristics of the complexes correlate with 
transfection yields of these two peptides.  Many studies have observed CD spectral 
changes in DNA or siRNA induced by nucleic acid packaging molecules and have 
reported very little signal for the packaging molecule itself 31; 51; 52; 53.  Observing 
secondary structure formation in H3K4b or H3K(+G)4b upon complexation with 
nucleic acid was of great interest to see if there is a recognizable structure for the 
complex.  The thermodynamics of the complexes formed with H3K4b and 
H3K(+G)4b can elucidate whether the type of bonds being formed are electrostatic, 
hydrogen bonding or van der waals during condensation of the peptide with nucleic 
acid.  The type of bonds that are driving formation of a delivery complex can give 
insight into how these complexes are formed.  The structural results yielded a 
surprising PII helical structure for the peptide alone.  ITC results demonstrated that 
complex formation is a two-step process with an initially enthalpically driven phase 
followed by an entropically driven phase. 
3.1 Materials and Methods: 
3.1.1 CD Analysis of H3K4b and H3K(+G)4b with and without Plasmid DNA or 
siRNA 
A Jasco-810 Spectropolarimeter was used to conduct all CD experiments.  




quartz cuvette with a pathlength of 0.2 cm was used.  The volume used was 300 µL 
for DNA and 270 µL for siRNA experiments.  A 20 mM phosphate buffer pH 7.5 
with 2 mM NaCl was used in all experiments: this was the maximum amount of 
chloride ion that could be used without unacceptably high absorbance at 190 nm.  For 
pH variation experiments 20 mM phosphate buffers at pH 7.5 and pH 5.78 were 
prepared.  Temperature was set to 4 0C, 25 0C and 60 0C using a Peltier element 
attached to the instrument.  For DNA experiments, 2 µM H3K4b or H3K(+G)4b was 
initially placed in the cuvette.  Successive 1 µL aliquots of from a 16 nM DNA stock 
were titrated into the cuvette yielding 0.05 nM per addition of DNA.  After a total of 
0.37 nM of DNA had been added to the peptide, aliquots of 1 µL from an 81 nM 
peptide stock were titrated into the cuvette, yielding 0.27 nM per addition of DNA.  
For H3K(+G)4b titrations, two 0.75 nM aliquots of DNA were added at the end of the 
titration.  For the siRNA experiments, 5 µM H3K4b or H3K(+G)4b were initially 
added to the cuvette.  Aliquots of 1 µL from a 12.1 µM siRNA stock were titrated into 
the cuvette yielding 0.045 µM additions of siRNA.  After a total of 0.43 µM of 
siRNA had been added to the peptide, aliquots of 0.5 µL from a 121 µM siRNA stock 
were titrated into the cuvette yielding 0.22 µM additions of siRNA.  After a total of 
1.21 µM siRNA was added, 1 µL aliquots from a 121 µM stock were titrated into the 
cuvette yielding 0.43 µM additions of siRNA.  After each aliquot was added, a CD 
spectrum was taken and changes in the CD signal were observed.  All spectra were 
buffer corrected by subtracting the 20 mM phosphate buffer with 2 mM NaCl 




3.1.2 ITC of H3K4b and H3K(+G)4b Plasmid Binding 
Szu-Ting (Justin) Chou generously conducted all ITC experiments and 
graciously allowed us the use of this data.  H3K4b, H3K(+G)4b (25 µM), and DNA 
plasmid (4.8 kb, 3.75 nM) were dissolved in phosphate buffer (10 mM, pH 7.3).  The 
thermodynamic profile of HK peptides DNA binding was obtained with the use of a 
VP-ITC (Microcal Inc.) at 37 °C.  The sample cell was filled with DNA plasmid 
(1450 µl), the syringe contained peptide solution (250 µl).  Injections (5 µl, a total of 
56 injections) were carried out at 10 s duration and 360 s intervals.  The dilution heat 
was determined with the titration of peptides into buffer without DNA.  Molar 
enthalpy and final figures were generated in Origin 5.0.  The binding study for each 
HK polymer was performed in duplicate.   
3.2 Results: 
3.2.1 CD Signal Characteristics of Peptide during Titration with Nucleic Acid 
CD analysis was conducted for both H3K4b and H3K(+G)4b peptides in the 
presence of siRNA and DNA, as seen in Figure 3.1.  Previous experiments conducted 
by Dr. Mixson’s laboratory demonstrated that H3K4b could form alpha helicies in the 
presence of trifluoroethanol (TFE), which is a known inducer of alpha helix 
formation.  Therefore, our expectation was that some alpha helix might form upon 
nucleation of the peptide on nucleic acid however, the data show no definitive 
organization into alpha helices or any other structure with increasing addition of 
siRNA or DNA.  H3K4b and H3K(+G)4b exhibit what most closely resembles a 




strong negative signal around 197 nm 
 
Figure 3.1 CD spectra of H3K4b or H3K(+G)4b titrated with siRNA or DNA.  The buffer used was 
20 mM phosphate with 2 mM NaCl at pH 7.5.  The top left CD spectrum is a titration of 5 µM 
H3K4b (powder blue circles) with siRNA ranging from 0.04 µM-4.7 µM (Red Gradient), which 
corresponds to a N/P ratio ranging from 192-1.8 N/P.  The siRNA alone signal at 4.06 µM is 
presented with dark red triangles.  The buffer signal is presented as grey diamonds and is 
subtracted from all other spectra.  (Top right) Titration of 5 µM H3K(+G)4b (blue circles) with 
siRNA ranging from 0.04 µM-5.9 µM (Red Gradient).  (Bottom left) Titration of H3K4b with 
plasmid DNA ranging from 0.1 nM-4.0 nM, which corresponds to an N/P ratio ranging from 
446-6 N/P, (Blue Gradient) into 2 µM H3K4b peptide (salmon circles).  The DNA alone signal for 
4 nM is presented with dark blue triangles.  (Bottom right) Titration of DNA ranging from 0.05 
nM-5.5 nM into 2 µM H3K(+G)4b peptide (Red circles). 
and a slight positive maximum around 222 nm.  The PII CD spectrum can be easily 
mistaken for a random coil signal because of the similarity in signal of a negative 
maximum at 197 nm.  However, the CD for a PII helix has a characteristic positive 
maximum at 222 nm, which decreases upon denaturation and gives a signal greater in 
magnitude than that of a random coil54; 55; 56.  There is a change in the signal with 
increasing amounts of siRNA or DNA.  We do not observe any clear structural 




presented.  There is a clear reduction of the peptide PII structure upon binding of 
nucleic acid during complex formation.  The DNA CD does not contribute a 
significant signal by itself, but we still see an effect on the peptide upon binding 
DNA.  At the end of the titration, in the case of siRNA, CD signal of the nucleic acid 
at high concentration is strong enough that it replaces the peptide signal.  The peptide 
alone shows a weaker CD signal in the DNA experiments because a lower 
concentration was used than in the siRNA experiments (to compensate for the 
significant differences in binding stoichiometry between siRNA and DNA).  There 
are some differences in the intensity of the CD signal between the two peptides, 
which is especially true for the 2 µM signal of H3K4b compared to that of 
H3K(+G)4b.  This could be due to difference in structural organization of each 
peptide.  Possible experimental error in the concentrations of each peptide could also 
be contributing to the differences observed, however checks of the peptide 
concentration with a UV-visible spectrophotometer proved that the concentrations in 
the cuvette are what they were believed to be. 
Since the only two major CD signals observed are that of the peptide and 
nucleic acid, we might expect that the a simple addition of the two signals are being 
observed during the titration.  However a Singular Vale Decomposition (SVD) and a 
3-state analysis of the data in matlab showed that this is not the case and that there is 
an independent signal for the peptide-nucleic acid complex. 
 The CD spectra acquired with titration of siRNA to H3K4b and H3K(+G)4b 
can be used to assess the different spectral components of peptide-siRNA mixtures.  




see if the siRNA-peptide complex formed has an independent CD signal compared to 
siRNA and peptide alone.  Initially, an unbiased singular value decomposition (SVD) 
was conducted to see if there are multiple spectral components to the CD signals.  
The SVD was able to pull out at least four independent signals from the siRNA 
titration of H3K4b (not shown).  Two of the spectral contributions closely resemble 
 
Figure 3.2 Added Independent siRNA and H3K4b Signals.  The CD spectrum on the left shows the 
independent signals for siRNA and peptide at 1 µM concentration.  When spectra for siRNA are 
added at their corresponding experimental concentration to 5 µM peptide, a theoretical set of 
spectra is obtained for the mixture of components (spectrum on right).  The additive spectrum 
does not resemble the experiment spectrum presented in the top left panel of Figure 3.1 
suggesting there is at least one missing component.   
the signal for siRNA by itself and the peptide by itself.  The other two signals 
obtained from the SVD were thought to be contributions from a unique signal for the 
siRNA-H3K4b complex formed.  As conformation of the existence of this 
independent signal, Figure 3.2 presents the spectrum we would expect to obtain if the 
CD signals for the siRNA and peptide were simply additive.  This additive 
reconstruction of the siRNA titration does not resemble the actual results, meaning 
there are contributions from at least one other spectrum.  A Matlab program was 
written to extract the unknown spectrum of the siRNA-peptide complex.  A general 
schematic of how the Matlab program was executed is given in Figure 3.3.  In the 




theoretical complex spectrum was created.  The spectral matrix of references was 
 
Figure 3.3 Components Used to Create the Theoretical Reconstruction of the Experiment.  The 
spectrum on the top left shows the CD for siRNA and peptide (blue) at 1 µM concentration.  
(Bottom left) A matrix of reference spectra for the peptide, the siRNA and unknown peptide-
siRNA (purple) complex was created.  (Top Middle) A graph of the concentration of free siRNA 
(orange), free peptide (Pink) and complex (green) is presented as siRNA is titrated.  (Bottom 
Middle) A matrix of these concentrations was created assuming stoichiometric binding between 
peptide and siRNA.  The reference matrix was multiplied by the concentration matrix, while 
minimizing the values for the complex spectrum and the binding stoichiometry that optimized 
the fit of the theoretical reconstructed data to the experiment (Top Right).  The minimization 
yielded a matrix of ellipticities for the theoretical reconstruction (Bottom Right) of the 
experimental data.   
then multiplied by a matrix containing the concentrations of each component at each 
point in the titration, assuming an unknown binding stoichiometry, that was also 
refined.  Multiplying these two matrices together generates a theoretical 
 
Figure 3.4 Theoretical Reconstruction of Experimental Spectra.  The spectrum on the left shows 
the siRNA and peptide spectra along with the spectrum for the siRNA-peptide complex, derived 
from the minimization described in the text at 1 µM concentration.  Multiplying this spectrum by 
the concentration matrix provided a theoretical reconstruction for the experimental data that’s 




reconstruction of the experimental 
data.  In order to obtain the H3K4b-
siRNA complex spectrum and 
binding stoichiometry, the 
difference between the experimental 
data and the reconstructed 
theoretical spectrum was minimized 
using the built in fmincon routine.  
The sum of squares of the elements 
of the error matrix was minimized 
by altering the spectrum for the 
H3K4b-siRNA complex and 
binding stoichiometry.  Best-fit 
stoichiometry of binding was 2.9 
peptides per siRNA.  At charge 
neutralization, assuming a positive 
24 charge for the peptide, we would 
anticipate 1.75 peptides, per 21 base  
Figure 3.5 Reference of Known CD Spectra.  CD spectra from three separate papers are 
presented in A57, B58, and C59.   The spectrum in A shows heat denaturation of an E. coli 5S RNA 
at 20 0C, 50 0C and 65 0C in circles, triangles and squares, respectively, which is representative of 
an RNA spectrum.  B shows heat denaturation of an (AT)3 duplex from 0 0C-95 0C, which is 
representative of a DNA spectrum.  The spectrum in C is a structural deconvolution of alpha 
helix (α), beta sheet (β) and PII (P2) helix spectra from reference spectra.  The peptide-siRNA 
complex spectrum obtained does not match any of these reference spectra. 
pair siRNA.  We are observing more peptides bound per siRNA than charge 




peptide.  The theoretical spectrum constructed from the siRNA, peptide and complex 
spectra are presented in Figure 3.4.  A series of reference spectra presented from other 
papers in Figure 3.5 shows CD spectra for thermal denaturation of DNA and RNA 
and reference spectra for alpha helices, beta sheets and a PII helix57; 58; 59.  The spectra 
for the thermal denaturation of DNA and RNA are the same as ideal reference spectra 
of B-form DNA and siRNA82; 108.  Our theoretical H3K4b-siRNA complex spectrum 
has a weak single intensity and does not appear to resemble any of these references.  
What we are most likely observing is either the disruption of the PII helix structure or 
possibly some denaturation of the siRNA upon complex formation. 
Taking into consideration the siRNA-peptide complex CD spectrum, the re-
constructed theoretical spectrum closely resembles that of the experiment.  The error 
between the experimental and theoretical curves is presented in Figure 3.6.  The error 
between the two sets of spectra appears to be relatively random, confirming our 
theoretical reconstruction.  There appears to be a group of slightly positive error 
curves around 200 nm for the siRNA lower concentrations (light blue lines).  For the 
higher concentrations (dark blue lines) there is a bias signal that is positive at 212 nm 
and negative at 197 nm.  The small bias in the error spectra is believe to come from a 
missing fourth spectrum for complex that is contributing to the experimental spectra.  
This fourth spectrum was predicted by the SVD and is believed to be an independent 
spectrum for further binding of siRNA to an already saturated siRNA-peptide 
complex.  However, an attempt to modify our model to fit for a fourth spectrum did 
not converge on an answer.  Due to errors in concentration and the quality of the data, 





Figure 3.6 Error in Experimental versus Theoretical CD Spectra.  The experimental spectrum (top 
left) were subtracted from the constructed theoretical titration spectrum (top right).  The 
resulting error spectrum (bottom blue) presents relatively small and random error between the 
two spectra.  There is a slight bias in the error, which may come from a fourth component in the 
experimental data that was not modeled. 
Both peptides binding to siRNA show very similar characteristics in the 
peptides’ CD signal change.  The decrease in peptide signal observed upon addition 
of siRNA was relatively reproducible and well behaved.  Little can be inferred about 
any difference between structural changes of H3K4b and H3K(+G)4b’s with binding 
of siRNA.  This fact alone does not preclude the idea that the two peptides have a 
different transfection ability based on there structural difference in binding siRNA, 
simply that we do not see these differences in CD analysis.  Local changes in the 




the differences in transfection observed could be due to large-scale structural 
differences. 
Changes in H3K4b and H3K(+G)4b signal are more inconsistent during DNA 
binding.  The first experiments conducted with addition of DNA to H3K4b, were 
similar to that of the siRNA.  An interesting result is observed during H3K(+G)4b’s 
binding with DNA because of the significant change in CD signal observed with the 
addition of only a small amount of DNA.  This was a very surprising result 
considering that only a very small fraction of the peptide should be interacting with 
 
Figure 3.7 H3K4b and H3K(+G)4b-DNA Complex Formation Repeated.  Titration of H3K4b and 
H3K(+G)4b with plasmid DNA was repeated to see if the large jump observed in the first DNA 
titrations could be repeated.  Repeated results resembled what is observed for titrations of 
siRNA to each peptide.  There is a slight increase in the peptide CD signal at low concentrations 
of plasmid DNA with an incremental decrease in peptide CD signal with increasing 
concentrations.  H3K4b and H3K(+G)4b both show similar changes in CD signal with addition 
of DNA in this experiment. 
the DNA at the 0.05 nM concentration of DNA (about 0.5% of the total peptides 
binding capacity at 2 µM).  When these experiments were repeated (Figure 3.7), the 
large decrease in CD signal we observed for H3K(+G)4b binding to DNA was not 
reproducible.  A slight increase in PII helix CD signal is observed at low DNA 
concentrations with a steady decrease in CD signal at higher concentrations.  The 
difference in reproducibility of results between the siRNA and DNA CD experiments 




formation.  There is a possibility that plasmid complex formation with each peptide 
could involve some cooperativity at lower peptide concentrations. 
3.2.2 Isothermal Titration Calorimetry (ITC) Results 
A large thanks goes to my collaborator, Szu-Ting (Justin) Chou, who 
generously conducted all ITC (Isothermal Titration Calorimetry) experiments and 
graciously allowed us the use of the preliminary data presented here with his 
permission.  His contributions to the analysis of this data proved invaluable in our 
understanding of the mechanics of the peptides’ interaction with plasmid DNA and 
siRNA. 
ITC was used to 
assess the thermodynamic 
contributions of PLL, 
H3K4b and H3K(+G)4b with 
plasmid DNA.  Difference in 
the binding interaction 
between H3K4b and 
H3K(+G)4b to plasmid DNA  
Figure 3.8 ITC of H3K4b H3K(+G)4b-DNA and PLL Complex Formation.  The enthalpy change of 
complex formation upon addition of H3K4b, H3K(+G)4b or PLL to DNA was measured.  PLL 
(green) complex formation with plasmid DNA demonstrates a very large enthalpy of formation 
compared to H3K4b or H3K(+G)4b.  Both H3K4b (blue) and H3K(+G)4b peptides interactions 
prove to be exothermic at low N/P ratios, which are characterized by stronger hydrogen bond 
formation between the peptide and DNA.  Upon addition of more peptide, the formation of 
complex with DNA changes over to being endothermic indicating a different thermodynamic 
driving force.  In this region of the reaction, electrostatic interactions and release of water and 
cations are driving the reaction.  H3K4b has a larger endothermic enthalpy of formation than 
H3K(+G)4b. 
can be elucidating by observing the complexes enthalpy of formation (Figure 3.8).  




ranging from 0 to 10.  The heat of formation for the peptide-plasmid complex was 
measured in kcal per mole of injected peptide.  The linear PLL peptide was used as a 
comparison to binding of each of the branched peptides.  PLL binding to plasmid 
demonstrates a large positive enthalpy, with very little exothermic contribution to 
complex formation.  Upon addition of low concentrations (0.5 N/P), binding of both 
H3K4b and H3K(+G)4b is exothermic.  Continued addition, above a 2 N/P ratio of 
peptide to plasmid switches over to an endothermic reaction.  At 1:1 charge 
neutralization, which is an N/P ratio of 3, the enthalpy of formation reaches a 
maximum.  At the 3 N/P ratio we observe a significant difference between peptides, 
where H3K(+G)4b has a lower heat of formation, at 26 kcal/mol compared to that of 
H3K4b at 48 kcal/mol.  Past a 3 N/P ratio the formation of the peptide-plasmid 
complex has completed and drops to 0 kcal/mol by about N/P equal to 6. 
3.3 Discussion: 
3.3.1 Random Coil and PII Helix Conformation in CD 
There is a large body of evidence that suggests what was previously thought 
to be “random-coil” structure is in fact not-so-random54.  Studies have been 
conducted on short poly-L-glutamic acid (PGA) and poly-L-lysine (PLL) peptides 
exploring this idea56; 62.  It is known that a polyproline peptide (PPL) assumes a left-
handed helix termed a poly-proline II (PII) conformation55; 60.  The structure of a PII 
helix as seen in the poly-proline crystal structure and a stretch of PII helix found in a 
Lignin Peroxidase are shown in Figure 3.961.  The CD of the PII conformation tends 




however there are two prominent differences observed from that of a random coil 
(Figure 3.10).  One is the fact that the negative peak is very strong for the PII 
 
Figure 3.9 Views of the PII Helix Structure.  Three views of the left handed PII helix structure are 
shown above.  (From left to right) A model of the PII helix determined from the crystal structure 
which shows three residues per helical turn60.  (Middle) A stretch of nine residues that forms a 
PII helical segment in Lignin Peroxidase are shown61.  The three proline and one lysine residue 
that strongly correlate to PII helix formation are highlighted in green.  The arrow is pointing 
down the central axis of the PII structure to show the counterclockwise corkscrew of the helix.  A 
cartoon of the same PII helix in Lignin Peroxidase is presented. 
conformation.  The other is a slightly positive peak in the 220 nm region.  The helical 
chain structure of the PII conformation has been confirmed by x-ray crystallographic 
analysis, confirming that the CD is that of a definitively structured peptide and not 
that of a randomly ordered, denatured structure60.  Collagen assumes a very similar 
helical structure to that of PPL54; 63 and the CD for collagen also shows a 
characteristic strong negative signal in the 200 nm range and a positive near 220 nm.  
When collagen is heat denatured, there is a significant drop in the CD signal for the 




disordered structure looks like: it has a much weaker CD signal overall and has only 
one negative peak 
around 200 nm54; 56.  
Polyglutamic acid 
(PGA) and PLL both 
show a very similar 
signal to that of PPL56; 
62.  This is a significant 
observation because 
PGA and PLL 
structures have 
previously been put 
into the category of 
random coil, which 
may have been the 
predicted result,  
Figure 3.10 CD Reference Spectra for a PII Helix Conformation.  Reference CD spectra of four 
different PII helix are used from a review article by Shi et al54.  Spectra of PII helix structures in 
their native and denatured state are presented from four different peptides; A, rat tail collagen; 
B, poly-L-proline II; C, polyglutamic acid; and D, poly-L-lysine.  All spectra show a decrease in 
the amplitude of PII helix spectra upon thermal denaturation. 
because, any significant structural ordering would not have been predicted for a small 
peptide.  Upon heat denaturation at 80 oC, there is a significant disruption of PGA and 
PLL’s PII conformation to form a disordered structure as seen in collagen56; 64.  With 
the evidence presented, we suggest that many short peptides that were thought to have 




3.3.2 Evidence for a PII Helical Conformation of H3K4b and H3K(+G)4b 
The CD data for H3K4b and H3K(+G)4b show the strong negative (197 nm) 
and a weak positive signal (222 nm) characteristic of the PII helix structure of PLL 
and PPL.  The presence of a definitive PII helical structure would account for why we 
have such a strong signal for peptide alone, instead of the relatively weak signal to be 
expected if this peptide were in a truly disordered state56.  Experimentation at low pH 
could reveal more about the structure of these peptides because it has been observed 
that PII helical peptides in the presence of low pH can result in a formation of α-helix 
structure in these peptides54.  When the pH was decreased from 7.5 to 5.78, an 
increase in our peptide signal was observed (Figure 3.11) but we did not observe any 
α-helix formation.  This 
result indicates the PII 
conformation of H3K4b and 
H3K(+G)4b is enhanced 
when a solution becomes 
more acidic.  A conclusive 
result contributing to this 
belief deals with the  
Figure 3.11 pH Dependence of PII Helix Structure.  A CD spectrum of H3K4b (blue) and 
H3K(+G)4b (red) in 20 mM phosphate buffer at pH 7.5 (dashed lines) and pH 5.8 (solid lines), 2 
mM NaCl is shown.  The characteristic PII structure with extremes at 197 nm and 222 nm is 
seen for the peptide as previously demonstrated.  At pH 5.8 there is to be an enhancement of the 
signal at 197 nm and 222 nm.  This could be an indication of stronger PII helical formation when 
the pH is decreased. 
PLL heat denaturation result presented by Tiffany and Krimm where PII helix CD 




temperature.  We conducted an experiment where we took each peptide and bound a 
very small amount of DNA, which still presented a very strong characteristic PII CD 
signal for the peptide (Figure 3.12).  The DNA was originally added to see if heat 
denaturation had any effect on the peptide-DNA complex, however what we ended up 
observing were changes in the peptide CD.  CD for the peptide was then collected at 
 
Figure 3.12 Temperature Dependence of PII Helix Content of H3K4b and H3K(+G)4b.  CD spectra 
of H3K4b, H3K(+G)4b in the presence of 2.6nM DNA (A) and poly-L-lysine (B) during heat 
denaturation of the peptides from 4oC-60oC.  Both peptides change in structure are compared to 
a references spectrum of poly-L-lysines change in structure as a function of temperature.  The 
Poly-L-lysines spectrum was used from a paper by Tiffany and Krimm56.  A.  A small amount of 
DNA was added to both peptides in order to assess whether or not there was a change in the 
peptide signal while in complex with DNA.  Both peptides are only at 8% of their total saturation 
and still have a very clear PII structure signal from the peptide alone.  The two peptides 
demonstrate an enhancement of PII helix structure when lowered to a temperature of 4oC.  Upon 
heating to 60oC, there is a significant decrease in the PII CD signal seen for the peptides.  H3K4b 
appears to be more strongly affected by thermal denaturation than H3K(+G)4b, highlighting 
differences in their thermal stability.  B. Poly-L-lysine heat denaturation.  The change in poly-L-
lysine CD signal as a function of temperature shows the exact same trend as for H3K4b and 
H3K(+G)4b, indicating both of these peptides melt. 
20 oC, then the temperature was dropped to 4 oC and increased to 60 oC and changes 
in the CD signal were observed, similar to Tiffany and Krimm.  The result shown in 
Figure 3.10 is almost identical to that of Krimm et. all showing a strong increase in 




apparent at 197 nm until the temperature is increased to 60 oC.  However, the changes 
at 222 nm are very clear and distinct, which is a defining characteristic of the PII 
conformation since random coil has no positive peak in the 220 nm region54; 65.  All 
of the evidence provides a strong case for H3K4b and H3K(+G)4b assuming a single 
or possibly multiple chain (in the case of collagen) PII conformation. 
3.3.3 Structural Characteristics of H3K4b and H3K(+G)4b that Allow PII Formation 
The major driving force that yields a PII conformation is believed to stem 
from the peptide backbone’s interaction with the solvent, in this case, water55.  It has 
been shown that peptides favor a PII conformation near neutral pH and low salt 
concentrations, which are similar to the conditions we have used to assess H3K4b and 
H3K(+G)4b55.  The increased accessibility of solvent to the peptide backbone of 
small peptides (such as glycine) and peptides with a flexible R group, enables this 
conformation to occur55.  Both peptides we have studied, H3K4b and H3K(+G)4b, 
are small branched peptides that contain histidine but also are comprised of about 
32% lysine as well.  PLL readily forms a PII helix which has been observed many 
times, leading to the idea that lysine could be an important amino acid in forming this 
structure54; 55.  This may suggest an interaction of the lysines in each of these 
branched peptides with the solvent.  In the case of H3K(+G)4b, the added glycines 
could be contributing more to solvent interactions.  In addition, side chain to 
backbone interactions could also play a role in forming this helix55.  A PII helix has 
Ramachandran angles (φ,ψ = -75o,145o) consistent with having three amino acid 




lysine branched peptides contain a lysine every four residues on each branch, which 
may indicate an interaction of the lysine with the backbone every four amino acids. 
In light of this comparative analysis, what is most likely happening with 
H3K4b and H3K(+G)4b peptides upon binding of nucleic acid is as follows: The 
peptide alone assumes a PII helix conformation.  Upon addition of increasing 
concentrations of siRNA or DNA, there is disruption of this helix structure upon 
association with nucleic acid.  Eventually, enough addition of nucleic acid completely 
disrupts this structure, and all peptide eventually is bound to siRNA or DNA.  DNA’s 
structure changes slightly upon addition of peptide and there is an independent CD 
signal for the peptide-nucleic acid bound complex.  The glycines in the H3K(+G)4b 
peptide may be contributing to slightly more PII structure formation because of the 
glycines greater rotational ability, allowing for greater solvent accessibility in this 
peptide55. 
3.3.4 Thermodynamic Contributions to H3K4b and H3K(+G)4b-Plasmid Complex 
Formation 
 Previous results with EtBr exclusion and DNase I degradation assays indicate 
H3K4b clumps up more on plasmid DNA forming regions of positive overcharge and 
naked regions of uncoated plasmid.  H3K(+G)4b coats plasmid better, forming more 
evenly distributed, neutrally charged complex.  DLS also demonstrates that a 
complex formed with H3K(+G)4b is larger, perhaps due to better charge 
neutralization.  The ITC data gathered gives some support to the idea of better coating 
for the H3K(+G)4b peptide compared to the aggregate structure of H3K4b.  There are 




demonstrated by the ITC.  The first phase is presumably initial binding of the peptide 
to excess DNA and the second is condensation accompanied by aggregation.  A two-
phase condensation of plasmid by electrostatic interaction with multivalent ions has 
been demonstrated previously66.  At low N/P ratios of peptide, an exothermic reaction 
occurs where heat is given off during complex formation.  Strongly exothermic 
reactions during peptide association with nucleic acid typically correlate to hydrogen 
bond formation67; 68.  Another possibility is a hydrophobic interaction between the 
peptide and DNA.  The hydrogen bonding interaction for these peptides are most 
likely coming from the histidines of the peptide, which has been demonstrated by 
NMR studies of the peptide-nucleic acid complex (Mixson lab, data unpublished).  
ITC experiments with PLL binding to DNA do not demonstrate the strong exothermic 
reaction observed for the branched peptide and primarily show an entropically driven 
reaction, which occurs from electrostatic binding.  The electrostatic interactions from 
the lysines are also contributing to the exothermic reaction observed for the branched 
peptide but apparently the total enthalpy for the reaction is negative. 
The condensation phase of complex formation is accompanied by a large 
positive enthalpy change starting around an N/P ratio of 3.  The endothermicity of 
this reaction means that it must be entropically driven66.  This result came as a 
surprise because the association of the peptide with the DNA might have been 
thought to be only an exothermic reaction.  A couple of factors that drive this unique 
complex formation were made clear by this result.  The major contribution to 
unfavorable enthalpy is probably the breaking of hydration bonds between the DNA 




proximity of the DNA during condensation by the peptide70.  The entropic driving 
force for this phase of the reaction is due to counterion release from the DNA upon 
electrostatic association of the ligand, which plays an important role in peptide and 
protein binding to nucleic acids66.  It is also important to mention the release of water 
from interaction with macromolecules can also play an important role in contributing 
to entropy66.  However, the release of counterions or water would be indistinguishable 
by ITC66.  This type of condensation through ion release has been experimentally 
shown by Matulis66.  In their experiment, multivalent cations used to associate with 
and condense DNA demonstrated a strongly endothermic, entropically driven 
reaction.  Initial electrostatic interaction of multivalent ions with DNA releases 
counterions.  Upon addition of enough multivalent ions to approach complete charge 
neutralization of the DNA there is further release of counterions from the DNA upon 
condensation of the structure.  In order for complete condensation of DNA to occur 
about 90% of the charge on the backbone must be neutralized70.  Interestingly, we 
observe a steep rise in endothermicity indicative of condensation between a 3 and 3.5 
N/P ratio.  Unlike this experiment, other ITC assays where drug binding to a protein 
site was assessed demonstrated an exothermic reaction that is characterized by 
hydrogen bond formation67.  However, the heat of formation for drug binding then 
plateaus once binding is complete, which we do not observe for binding of H3K4b 
and H3K(+G)4b to plasmid67.  The interaction of these peptides with plasmid 
resembles that of a zipper; it takes enough favorable interactions to get started, but 
once a critical amount of interactions occur (probably close to charge neutralization), 




starts condensation of the plasmid complex.  Upon reaching 90% charge 
neutralization, there is complete condensation of the complex.  Once the complex 
condenses and is close to neutral charge at a 3 N/P ratio, subsequent aggregation can 
then occur.  The thermodynamic mechanism proposed for H3K4b and H3K(+G)4b 
complex formation is a prime example of contributing energetic factors that appear 
relatively simple, but where the underlying chemical contributions are a combination 
of different factors. 
There is one clear difference in the thermodynamics of complex formation for 
these two peptides.  During the condensation phase, H3K4b has a about two times the 
enthalpy of formation compared to H3K(+G)4b.  H3K4b does not coat plasmid DNA 
well as indicated by the DNase I assay.  This leaves regions of uncoated, charged 
plasmid and overcharged areas of aggregated peptide, which creates a greater 
opportunity for further electrostatic aggregation demonstrated by H3K4b’s higher 
enthalpy of formation in the ITC.  H3K(+G)4b coats the plasmid DNA more evenly, 
not leaving regions of aggregated peptide or uncoated DNA.  This means once the 
plasmid is coated, there will be little to no electrostatic interactions between the 
peptide and plasmid because it will be charge neutralized.  Charge neutral plasmid 
complexes formed with H3K(+G)4b will undergo aggregation, however there is no 
further electrostatic interaction, yielding a less positive enthalpy of formation 
compared to H3K4b.  These data corroborate the idea that H3K4b forms more 
aggregate structure with more electrostatic interactions between uncoated regions of 
plasmid.  H3K(+G)4b coats the plasmid DNA more effectively forming less 




4. Chapter 4:  Morphology of Poly-Histidine Lysine-Peptide 

















Understanding morphological characteristics of the peptide-nucleic acid 
complex may be revealing as to compactness of packaging between individual 
molecules.  The objective was to assess differences in the size and morphology of the 
complexes formed with H3K4b compared to H3K(+G)4b.  Comparison of complex 
formation between the two peptides using Dynamic Light Scattering (DLS) and 
Atomic Force Microscopy (AFM) revealed larger sizes for H3K(+G)4b-plasmid and 
H3K4b-siRNA.  DLS analysis demonstrated a change in the size of complex formed 
with H3K(+G)4b-plasmid and H3K4b-siRNA while only small changes in size were 
observed for H3K4b-plasmid and H3K(+G)4b-siRNA complexes.  AFM analysis 
presented a greater height to diameter ratio for H3K(+G)4b-plasmid and H3K4b-
siRNA, demonstrating a more rigid complex. 
4.1 Materials and Methods: 
4.1.1 DLS Measurement of H3K4b and H3K(+G)4b-DNA and siRNA Complexes 
Experiments were conducted on a Zetasizer Nano ZS90 under the supervision 
of Dr. Robert Bonenberger who runs the Modern Engineering Materials Instructional 
Laboratory in the Kim Engineering building.  The Zetasizer Nano ZS90 is fitted with 
a 633 nm laser and scans are taken at 90o to the sample chamber.  A siliconized 700 
µL Helma fluorescence cuvette was used for these experiments.  A 250 µL volume of 




the siRNA and DNA experiments containing.  This volume was chosen to meet the 
sample height criteria of the DLS (between 10-15 mm).  For the siRNA experiments 
1430 nM H3K4b or H3K(+G)4b and 286 nM siRNA (which is 102,960 nM Nitrogens 
and 12,012 nM Phosphates) were added to the cuvette to form complex.  The DNA 
experiments used 750 nM H3K4b or H3K(+G)4b in combination with 5 nM DNA 
(Which is 54,000 nM Nitrogens and 30,000 nM Phosphates).  The concentrations 
corresponded to a 8.6 N/P ratio for the siRNA experiments and a 1.8 N/P ratio for 
plasmid experiments.  The N/P ratios for the siRNA experiments were well above 1:1 
charge neutralization of the siRNA.  N/P ratios for the DNA experiments were over 
half of 1:1 charge neutralization of the plasmid DNA.  The nucleic acid 
concentrations were chosen as the appropriate concentrations needed to see the 
complex in the DLS.  To see a particle size of 100 nm in diameter, a concentration of 
0.01 g/L is required.  All components were added to the cuvette and pipetted up and 
down and finger tapped to mix.  For assessment of the effect of salt concentration on 
complex formation, the 1x TEN, a 0.5x TEN (10 mM Tris, 1 mM EDTA, 50 mM 
NaCl pH 7.5) and autoclaved filtered water were compared.  The samples were 
allowed to incubate for 30 minutes.  Sample readings were taken over the course of 
two hours due to the time required to take readings of each sample.  Over the 2 hour 
time period, measurements of the effect of salt concentrations on particle size were 
conducted.  DLS measurements of peptide-nucleic acid complex freshly prepared in 
water were acquired right after sample mixing and were compared to samples 
prepared in water and incubated for >2 hours.  A time course of the experiment was 




sample immediately after peptide and nucleic acid were mixed.  Subsequent readings 
were taken 10 and 22 min after mixing.  The low volume glass cuvette option was 
used in the instrumentation software.  In the software the dispersant selected was 
water.  The material being analyzed was chosen as protein.  Each size distribution is a 
scan of 20 readings taken for 15 seconds each combined by the instrument software.  
The DLS diameters were reported by the instrument as a log scale and then plotted on 
a log scale in prism.  This made the sizes reported evenly spaced as a histogram 
distribution when plotted in prism. 
4.1.2 AFM Binding to DNA and siRNA 
 Jason Hustedt generously conducted all AFM visualization experiments and 
graciously allowed us the use of this preliminary data. 
Equal volumes of H3K4b or H3K(+G)4b and siRNA were combined to form 
complexes for visualization.  The same was done for H3K4b or H3K(+G)4b and 
DNA complex formation.  The final peptide and DNA concentration were 120 µM 
and 65.8 µM, respectively.  Peptide and siRNA concentrations were 58.7 µM and 20 
µM, respectively.  After combining peptide with either siRNA or DNA, the complex 
was allowed to form and incubate for 30 min.  After incubation, the peptide-nucleic 
acid complexes formed were applied to a freshly cleaved mica surface.  The samples 
were imaged in air with no treatment of the surface.  Imaging was conducted with 





4.2  Results: 
4.2.1 DLS of Formed Complex 
DLS measures the hydrodynamic diameter of a particle, which is a measure of 
how a particle diffuses in a fluid.  The diffusion of a particle is measured by 
illuminating the sample with a laser and observing the Brownian motion of the 
particles.  Larger particles will diffuse slower than smaller particles.  The duration of 
diffusion in the laser is the basis for the time correlation function, which then used to 
measures the size of the particle.  The DLS analysis was conducted to observe any 
differences in size of complexes formed with H3K4b and H3K(+G)4b.  In addition, 
large-scale aggregation and precipitation was a concern with the complexes we were 
forming and the DLS is sensitive to large particles.  Both H3K4b and H3K(+G)4b 
peptides were combined with what was originally thought to be an equal charge ratio 
of siRNA and DNA to yield a charge to charge ratio of 1:1 and sizes of the complex 
were measured. Experiments with DNA yielded an N/P ratio of 1.8, which is below 
charge neutralization of the plasmid.  For siRNA experiments, an N/P of 8.6 was used 
which is well above saturation and charge neutralization of the siRNA.  Each peptide 
shows a different size from each other with binding to DNA or siRNA over a 22 
minute time period (Figure 4.1, Table 4.1).  Figure 4.1 shows the DLS intensity 
distribution for the size of particles formed with H3K4b or H3K(+G)4b in complex 
with DNA or siRNA and the values for the peak intensities of each size distribution 
are presented in Table 4.1.  The Polydispersity (PDI) is a measure of how uniform the 




particle is.  The PDI for peptide-DNA complexes were lower on average, around 0.26 
 
Figure 4.1 DLS Analysis of Peptide-Nucleic Acid Complexes Size over Time.  H3K4b and 
H3K(+G)4b-DNA and siRNA complexes formation in 1x TEN for 0 and 22 minutes.  The percent 
intensity on the y-axis is a measure of the intensity of laser light scattering for a given size 
particle.  A. Complex formation with 5 nm DNA and 750 nM H3K4b or H3K(+G)4b.  Change in 
size of the complex is seen by a shift of the maximum peak of the distribution, primarily for 
H3K(+G)4b.  B. Complex formation with 286 nm siRNA and 1430 nM H3K4b and H3K(+G)4b.  
For siRNA, change in the size of the complex is seen by a shift in the maxima size distribution 
peak for both peptides.  A small peak at 3.6 nm for 22 min H3K(+G)-siRNA complex formation 




 0 min. Particle Size at 
Peak Intensity 
22 min. Particle Size at 
Peak Intensity 
H3K4b-DNA 255-295 nm 295 nm 
H3K(+G)4b-DNA 531 nm 955 nm 
H3K4b-siRNA 531 nm 825 nm 
H3K(+G)4b-siRNA 295 nm 396 nm 
Table 4.1 Sizes of Peptide-siRNA and Peptide-DNA Complexes.  The size associated with the 
maximum percentage of intensity for each complex is reported in this table.  The size of 
complexes are presented for siRNA and DNA complexes at 0 min and 22 min.  Change in size of 
the H3K(+G)4b-DNA complex is seen by an increase in the maximum peak of the size 
distribution.  For siRNA, change in size of the complex is seen by a shift of the maxima size 
distribution peak for both peptides. 
for both H3K(+G)4b-DNA and H3K4b-DNA compared to siRNA complexes.  DLS 
measurements of Plasmid DNA, siRNA, H3K4b and H3K(+G)4b alone were taken to 
ensure that the sizes observed for the complexes were not the same as the individual 
components (Figure 4.2, 
Table 4.2).  H3K4b-DNA 
particles stayed smaller in 
size over time with a peak 
diameter of 295 nm.  In 
contrast, the H3K(+G)4b-
DNA particles appear to be  
Figure 4.2 DLS Analysis of siRNA, DNA and Peptide Sizes.  Size distributions for siRNA, DNA, 
H3K4b and H3K(+G)4b-DNA in 1x TEN are presented.  Both peptides proved to be small in size 
with some aggregates up to a couple hundred nm in diameter.  siRNA is also small in size, 
measuring 5.6 nm in diameter.  Plasmid DNA has a peak at 2.3 nm and 51 nm.  The peak at 51 
nm is most likely for the supercoiled DNA. 
much larger, increasing from 531 to 955 nm in diameter over 22 minutes.  This 




occurring for the two peptides with DNA.  The H3K(+G)4b-DNA complexes appear 
to aggregate over time, but the H3K4b-DNA complexes do not show aggregation.   
 Particle Size at Peak Intensity in 1x TEN 
Plasmid DNA 51 nm, 2.3 nm 
siRNA 5.6 nm 
H3K4b 0.96 nm 
H3K(+G)4b 4.8 nm 
Table 4.2 Control for the Size Measurements of Each Component.  The size of plasmid DNA, 
siRNA, H3K4b and H3K(+G)4b are presented above.  All molecules by themselves are 
significantly smaller in size than any of the complexes formed between peptide and nucleic acid. 
Peptide-siRNA complex formation showed a much higher PDI of 0.3 to 0.5 for 
H3K4b and H3K(+G)4b, respectively, indicating that there is a very large distribution 
in particle size for peptide-siRNA particles.  With H3K4b-siRNA complexes, there is 
a change in size from 531 nm to 825 nm in diameter over 22 minutes.  For 
H3K(+G)4b-siRNA complex, there is an increase in the size of complex ranging from 
295 to 396 nm.  In the case of peptide binding to siRNA, the H3K4b-siRNA complex 
has an increase in particle size due to aggregation of the complex while the 
H3K(+G)4b-siRNA size stays relatively constant over time.  The size results seem to 
be flipped between the two peptides depending on whether or not it binds siRNA or 
DNA.  The above-mentioned diameters for the peptide-nucleic acid complexes were 
obtained in 100 mM NaCl.  It is clear from these observations that time and possibly 
salt concentration had an unanticipated impact on peptide-nucleic acid particle size. 
4.2.2 Salt and Time Dependence on Peptide-Nucleic Acid Particle Size 
It has been shown that salt concentration can have a large influence on the size 
of the peptide-nucleic acid complex, most likely due to charge neutralization between 
particles formed71.  To probe the effect of NaCl on complex aggregation, the same 




mM NaCl as used previously and also in water with no NaCl.  It was thought that 
decreasing the salt concentration would have an effect on the aggregation of the 
 
Figure 4.3 Comparison of Particle Size in 1x TEN to Water.  DLS analysis of H3K4b and 
H3K(+G)4b-DNA and siRNA complex formation in 1x TEN or water.  A. DLS analysis of 
peptide-DNA complexes.  B. DLS analysis of peptide-siRNA complexes.  H3K4b complexes show 
a greater change in size in the presence of water compared to 1x TEN.  H3K(+G)4b complexes 
show more resistance to change in particle size between the two solvent conditions. 
complexes.  If there is no salt to shield charge and for counterion release, we should 




distribution found in water compared to 100 mM NaCl.  For H3K4b-siRNA and 
H3K4b-DNA complex formation, particles were significantly smaller in the absence 
of 100 mM NaCl (size results are presented in Table 4.3).  H3K4b-DNA dropped  
 Particle Size at Peak 
Intensity in 1x TEN 
Particle Size at Peak 
Intensity in H2O 
H3K4b-DNA 255 nm 59, 5.6 and 0.8 nm 
H3K(+G)4b-DNA 342 nm 1.1 µm 
H3K4b-siRNA 1.5 µm 164-190 nm 
H3K(+G)4b-siRNA 825 nm 712 nm 
Table 4.3 Comparison of Particle Size in Buffer Compared to Water.  DLS analysis of H3K4b and 
H3K(+G)4b-DNA or siRNA complex formation in 1x TEN, 100 mM NaCl or H2O.  The size 
associated with the peak intensity for each complex is reported in this table.  A decrease in 
complex size is very clear for H3K4b with removal of NaCl.  H3K(+G)4b-DNA complex size are 
smaller than seen previously in Table 4.1 and show an increase in size in the absence of NaCl  
H3K(+G)4b-siRNA demonstrates less change in particle size. 
from 255 nM in size to 59 nm and smaller size particles and H3K4b-siRNA dropped 
from 1.5 µm to between 164-190 nm.  For H3K4b-DNA complexes, the 5.6 and 0.8 
nm particles could be small aggregates of peptides and individual peptides based on 
their small diameter.  Sizes observed for H3K4b-DNA and H3K4b-siRNA complexes 
in NaCl were very similar to what was observed previously in Figure and Table 4.1.  
In contrast, The H3K(+G)4b peptide showed a greater resistance to change in particle 
size in the presence of water, which is a surprising result.  H3K(+G)4b-DNA complex 
demonstrated a relatively significant increase in size in water, however the complex 
size observed in 100 mM NaCl was smaller than observed previously (Table 4.1).  
H3K(+G)4b-siRNA complex showed a much larger size for complex formation that 
observed before which stayed relatively the same size in water.  The size results for 




with what was observed in our previous DLS experiment, demonstrating a much 
larger size of particle formation than was expected.   
 
Figure 4.4 Time Dependent Formation of Peptide-Nucleic Acid Complexes in Water.  DLS analysis 
of H3K4b and H3K(+G)4b-DNA and siRNA complex formation in water with more or less than 
30 min incubation.  A. DLS analysis of peptide-DNA complexes.  B. DLS analysis of peptide-
siRNA complexes.  Complexes formed with H3K(+G)4b showed a decease in size when freshly 
prepared compared to a long incubation period in water.  H3K4b complexes demonstrated less 




The only logical explanation that might describe the differences between 
observations in Figure 4.1 and 4.3 is the time dependence of forming peptide-nucleic 
acid complexes.  For the DLS experiments conducted in Table 4.3 the first sample 
that was measured was 30 minutes after preparation.  Subsequent measurements took 
place over a 2 hour time period.  This means that the siRNA samples, which were the 
last to have a reading taken, were allowed to form for 1-2 hours.  Previously, the 
complexes were only allowed to form for up to 22 minutes (Table 4.1).  This 
observation was only a bi-product of the actual experiment that was intended, but, 
had to be explored in more detail.  Therefore, a series of freshly incubated peptide-
DNA and siRNA samples were created in water and readings were taken immediately 
after mixing (Figure 4.4, Table 4.4).  Figure 4.4 shows that for H3K(+G)4b-nucleic  
 Particle Size at Peak 
Intensity  <30 min 
Incubation in H2O 
Particle Size at Peak 
Intesnity  >30 min 
Incubation in H2O 
H3K4b-DNA 459 nm 59, 5.6 and 0.8 nm 
H3K(+G)4b-DNA 459 nm 1.1 µm 
H3K4b-siRNA 190 nm 164-190 nm 
H3K(+G)4b-siRNA 105 nm 712 nm 
Table 4.4 Sizes of Peptide-Nucleic Acid Complexes with Different Durations of Incubation in 
Water.  DLS analysis of H3K4b or H3K(+G)4b-DNA or siRNA complex formation in H20 with 
more (scans greater than 30 minutes were take between 1-2hours after combining components) 
or less (scans less than 30 minutes were taken 4 minutes after combining components) than 30 
minutes of incubation.  Complexes formed with H3K(+G)4b, which showed an unexpectedly 
large size in the presence of water in previous results (Table 4.3), decreased in size when freshly 
prepared.  H3K4b-DNA complexes demonstrate an increase in the size of complex formed. 
acid complexes there is a decrease in the size of the complex when freshly prepared.  
H3K4B-DNA is the only complex where there was an increase in size when freshly 
prepared.  This could just be an increase in particle aggregation for this particular 




preparation or the salt content, suggesting time and salt concentration are important 
factors to consider when looking at the size of these complexes. 
4.2.3 AFM Images of H3K4b and H3K(+G)4b-Nucleic Acid Complexes 
A huge thanks goes to my collaborator and lab member, Jason Hustedt, for 
conducting an analysis of all AFM images acquired of H3K4b and H3K(+G)4b with 
plasmid DNA and siRNA.  The AFM analysis here is preliminary data presented with 
permission from Jason Hustedt.  A comprehensive understanding of H3K4b and 
H3K(+G)4bs interaction would not have been possible without Jason’s thoughtful 
insight and analysis of the AFM data. 
AFM images were obtained for H3K4b or H3K(+G)4b with either plasmid 
DNA or siRNA.  Ratios of peptide-nucleic acid prepared in water were the same as in 
transfection experiments conducted in the Mixson lab.  After complexes were allowed 
to form, they were pipetted onto a mica surface and imaged by the AFM.  
Topographical and phase images are presented for each complex formed with H3K4b 
or H3K(+G)4b and plasmid DNA in Figure 4.2.  Topography images are acquired by 
observing differences in oscillation of the cantilever as it scans across the surface.  
The oscillation amplitude of the cantilever will change as it scans across areas with 
raised surfaces.  Phase imaging looks at the phase shift in the oscillation of the 
cantilever as it interacts with the material on the surface.  The hydrophilic tip interacts 
with variations in the surface and peptide-nucleic acid complexes we are observing.  
These variations will cause a shift in the phase of the cantilever oscillation, which can 




Both peptides formed complexes that yielded sphere-like particles on the mica 
 
Figure 4.5 AFM Images of H3K4b and H3K(+G)4b-DNA Complexes.  Topography (Top two 
panels) and phase (bottom two panels) images are presented for complexes formed with H3K4b 
and H3K(+G)4b with plasmid DNA.  Topography images are presented in the top panels and 
phase images in the bottom panels.  H3K4b forms smaller aggregate structures on the surface.  
Larger complexes of H3K(+G)4b appear to be an aggregation of smaller, blob-like structures, 
which can be seen in the large aggregate highlighted by the white box. 
surface.  H3K4b-plasmid complexes formed are slightly smaller in size than 
H3K(+G)4b having a maximum height of about 11.1 nm giving a smaller height to 
diameter ratio.  Formed H3K(+G)4b-plasmid DNA complexes demonstrated a larger 
structure with a maximum height of 50.9 nm yielding a larger height to diameter 




structures that are aggregated together.  Demarcations of individual complexes that 
 
Figure 4.6 AFM Images of H3K4b and H3K(+G)4b-siRNA Complexes.  Topography (top two 
panels) and phase (bottom two panels) images are presented for complexes formed with H3K4b 
and H3K(+G)4b with siRNA.  Topography images are presented in the top panels and phase 
images in the bottom panels.  Complexes formed with H3K4b appear to be larger.  H3K4b 
complexes demonstrate a more evenly distributed material.  H3K(+G)4b particles are seen to be 
much smaller in size and are sparsely distributed on the surface. 
are aggregated together are clearly visible in the phase image of H3K(+G)4b-DNA 
complexes. 
Complexes formed with H3K4b and siRNA are much more uniform in size 
and morphology, compared to H3K(+G)4b-siRNA complexes, based on their 
appearance (Figure 4.3).  Particles formed with H3K4b hold their spherical nature 
very well with a maximum height of 107.7 nm, giving a larger height to diameter 




greater extent on the surface with a maximum height of only 16.4 nm, yielding a 
much smaller height to diameter ratio. 
4.3 Discussion: 
4.3.1 Important Considerations in Peptide-Nucleic Acid Particle Formation 
 Some limited conclusions can be drawn for the observations made in the DLS 
analysis between H3K4b and H3K(+G)4b particle formation with nucleic acids.  
H3K(+G)4b-DNA particle formation was the most consistent in size out of any 
complex formed, giving the lowest PDI range, between 0.15-0.26.  In general, 
peptide-siRNA complexes had a higher range of PDIs, from 0.16-0.48, indicating a 
very broad distribution of particle sizes.  The difference in PDIs observed could be 
indicative of the overall stability of particle formed with DNA is higher compared to 
that of siRNA.  Because of the DNA’s larger size, it nucleates many more peptides 
per molecule to form an individual complex.  Therefore, larger aggregates of particles 
are a combination of smaller, more stable nucleated particles.  In the case of the 
siRNA, N/P ratios are relatively high (N/P 8.6) meaning there is a significant excess 
of peptide.  The excess peptide could be having an impact on the consistency of 
particle size.  In addition, the change in particle size over time could make a strong 
case for charge neutralization of individually packed nucleic acids.  For example, 
H3K(+G)4b-DNA complexes shows a significant change in size over time compared 
to that of H3K4b-DNA.  If H3K(+G)4b is more completely coating the DNA and 
neutralizing more charge from the phosphate backbone of the DNA, this would allow 




DNA complex formation are also conducted below a 1:1 charge neutralization ratio 
(N/P 1.8) which may indicate that H3K(+G)4b is coating DNA more completely at 
lower N/P ratios.  However, The presence of both NaCl and duration of incubation 
have a large impact on particle formation with both peptides.   
DLS Data gathered previously from the Mixson lab demonstrated the size of 
these complexes is smaller overall in water than in a buffering system containing salt 
(Mixson: unpublished results).  Mixson has shown that complexes are smaller (on the 
order of 250 nm) when formed in the presence of water, which correlates to our 
findings.  When complexes are formed in Opti-MEM solution, which is a reduced 
serum transfection media, they are shown to have a much larger complex diameter, 
ranging on the order of micrometers.  This leads to the conclusion that peptide-
nucleic acid particles formed in buffering solutions containing salt and other additives 
could have the possibility to aggregate into large polyplexes.  Extended incubation of 
H3K4b and H3K(+G)4b with nucleic acid can also lead to the formation of large 
aggregates as seen in Figure 4.3.  Therefore if an ideal size of particle is desired for 
transfection, time and salt concentration will have to be carefully monitored. 
Some studies have indicated that ideal size for optimal uptake of nanoparticles 
is on the order of 100 nm in diameter72.  Particles greater than 500 nm in size, 
aggregate around the cell surface and show limited cellular entry72.  However, it has 
been reported in some cases that particles greater than 500 nm in diameter have had 
better success in delivering transfection than smaller particles72; 73.  In general, uptake 
will be a product of the route of entry of the particle.  Intuitively, smaller particles 




and be more readily taken up by the cell.  For particles around 100 nm in diameter, 
caveolin and clathrin-mediated endocytosis are the cellular entry route73.  For 
particles much larger in size, greater than 1 µm, the macropinocytosis path can allow 
entry of these molecules73.  It will be important to the future analysis of gene delivery 
particles to take into consideration all potential pathways of entry73. 
4.3.2 Calculations of Nucleic acid and Peptide Contained in a Complex 
In addition to the route of entry, the size of the particle can determine the 
amount of genetic material contained inside.  With the data gathered about the 
hydrodynamic diameter of the complex, a series of simple calculations can be 
demonstrated to yield an approximate value for how many nucleic acids and peptides 
are contained in a given size complex.  For supercoiled DNA, our DLS results 
measured a 3 kb plasmid to have a diameter of 51 nm.  This is a reasonable 
approximation considering other supercoiled plasmids of a similar size have 
measured around 100 nm in diameter74.  First, we can calculate the volume of our 3 
kb plasmid given the diameter and using the calculation for the volume of a sphere, 




d = 51 nm
V =
! 51 nm( )3
6




To compare to the value obtained above, the volume DNA occupies if it were a 3 kb 
cylindrical rod will be calculated.  B-form DNA is about 0.34 nm per base pair and 
pRset is 3 kb long. 
3, 000 bp * 0.34 nm / bp=1,020 nm  
A 3 kb plasmid is 1,020 nm in height and B-form DNA has a diameter of 2 nm.  
Using the formula for the volume of a cylinder, we can calculate the volume occupied 
by our DNA as a rod. 




V = ! (2 nm)
2 (1,020 nm)
4
= 3, 204 nm3  
If we take the volume above and plug it into the equation for the volume of a sphere, 
we can get the diameter of that sphere. 
d = 3, 204 nm
3  * 6
!
3 =18 nm  
The diameter for the sphere calculated for the volume of the rod is smaller (18 nm) 
compared to that of the experimental value for diameter.  In addition, the volume 
occupied by the rod is about 10 fold smaller than that of the sphere estimated from the 
experimental diameter of a plasmid, presenting a range of sizes for the volume 
occupied by the DNA. 
To calculate the volume occupied by the 21mer siRNA used in the DLS 
experiments, the estimated dimensions of a 21mer A-form RNA were used to 
calculate the volume of a cylindrical rod.  A-form RNA is about 0.24 nm per base 




21 bp * 0.24 nm / bp = 5.04 nm  
A 21 bp siRNA is 5.04 nm in height and A-form RNA is 2.3 nm in diameter.  Again, 
using the equation for the volume of a cylinder we can calculate the volume. 
V = ! (d)
2h
4
V = ! (2.3 nm)
2 5.04 nm
4
= 21 nm3  siRNA
 
The volume of a 3 kb B-form DNA rod is 3,204 nm3 and of a 21 bp siRNA rod is 21 
nm3. 
The peptide molecule itself is small in size, however, because of the sheer 
quantity bound, they will likely take up space inside the particle.  An assumption will 
be made that the volume of the peptide will occupy about half of the volume of the 
complex, if there is complete coating of the nucleic acid.  A similar assumption will 
be made for the siRNA-peptide particles as well.  Smaller size H3K4b and 
H3K(+G)4b-nucleic acid bound particles are around 100 nm in diameter.  The 
volume of a particle of such size is as follows: 
V = ! (100 nm)
3
6
= 523, 599 nm3  
Only half of this volume will be occupied by the nucleic acid. 
523, 599 nm3
2
= 261,800 nm3  
Now we know the volume of a 100 nm particle and what volume a 3 kb packaged 
plasmid DNA occupies according to the experimental data, so we can figure out 





69, 456 nm3 / 3 kb plasmid
= 4 plasmids / 100 nm  
We can also calculate the number of plasmids that will be in a 100 nm particle if we 
assume the volume calculated for our B-form DNA rod is correct. 
261,800 nm3
3, 204 nm3  / 3 kb plasmid
= 82 plasmids / 100 nm  
For siRNA we can do a similar calculation based on the volume an A-form siRNA 
rod occupies: 
261,800 nm3
21 nm3  / 21mer siRNA
=12, 467 siRNAs / 100 nm  
The two values for the amount of DNA contained in a 100 nm particle, are different 
based on either the volume occupied by the supercoiled DNA or a DNA as a 
cylindrical rod.  A particle 100 nm in diameter containing 4 plasmids seems 
reasonable but could be an underestimation.  The value of 82 plasmids per 100 nm 
particle, for the volume of the DNA as a rod, is also a reasonable estimation but could 
be on the high end.  Using the DNA rod volume estimation for the number of nucleic 
acids per a particle, the number of peptides in a 100 nm particle can be estimated. 
If we assume a binding stoichiometry of 250 peptides bound per plasmid for 
complete charge neutralization (6,000 phosphates for a 3,000 bp DNA), we can also 
calculate the number of peptides per complex (since the volume of the peptides is half 
the volume of the sphere). 
82 plasmids * 250 peptides / plasmid=20,500 peptides  
We assume 1.75 peptides bound per siRNA for charge neutralization (42 phosphates 




12, 467 siRNA * 1.75 peptides / siRNA=21,817 peptides  
With the above calculations we now can estimate that there are about 82 plasmids and 
20,500 peptides per 100 nm particle.  For siRNA-peptide complexes there are 12,467 
siRNAs and 21,817 peptides per 100 nm particle.  Typically the sizes seen for the 
peptide-plasmid or siRNA particles are anywhere between 200-800 nm in diameter, 
which means there will be more plasmids, siRNAs and peptides (scaling with the 
cube of the diameter) inside any given complex.  There is a large room for error in 
these estimations, by a factor of ten as shown by difference in the calculated amounts 
of plasmid based on the volume occupied by a supercoiled DNA as a sphere 
compared to the volume occupied by a rod. 
Biological systems have a much more efficient means of packaging nucleic 
acids, which H3K4b and H3K(+G)4b may not be able to emulate.  A virus particle’s 
capsid, which contains the genetic material can range from 20-120 nm in diameter75.  
In the case of the Herpes-simplex virus, a 152 kb double-stranded linear DNA is 
stored in a 125 nm in diameter viral capsid76; 77.  Thus, viruses will be representative 
of the most efficient use of space for packaging of genetic material that nature can 
afford.  The Herpes capsid is about the same diameter as our 100 nm particle.  We 
can calculate how many 3 kb plasmid DNA molecules can be contained in the capsid 
based on the fact it holds up to 152 kb of DNA. 
152 kb
3 kb
= 51 plasmids  
A Herpes capsid 125 nm in diameter could hold up to 51 plasmids 3 kb in size.  For 
comparison to a different virus, a T7 bacteriophage capsid is 60 nm in diameter and 






=13 plasmids  
On average, a virus capsid about 100 nm in diameter would be able to hold between 
20-50 3 kb plasmids.  Our estimations predicted of about 82 plasmids per 100 nm 
particle, which is still high compared to the amount of genetic material a virus can 
hold.  It is unlikely that packaging of the H3K4b or H3K(+G)4b with DNA or siRNA 
will be as effective as a virus, so the amount of nucleic acid held in a complex formed 
with these peptides will be significantly less.  Taking into consideration the 
calculations made for the virus, the calculated range of 4-82 plasmids held per 100 
nm particle and the possibility for further compaction of the plasmid upon 
complexation with the peptide, the amount of nucleic acid held will most likely be on 
the order of 10s of plasmids per particle.  Overall, the calculated estimates amount of 
siRNA’s and DNA’s in a given particle makes available information about the 
amount of genetic material contained for delivery to the cell. 
4.3.3 AFM Morphology and DLS Assessment of H3K4b and H3K(+G)4b-Nucleic 
Acid Complexes 
AFM images and DLS of H3K4b or H3K(+G)4b complex formation with 
siRNA or DNA provide insight on the morphology of nucleic acid delivery 
complexes.  Differences in H3K4b and H3K(+G)4b morphology can provide a 
connection between the biological function of these peptides and how they appear.  
The AFM images of H3K4b-plasmid and H3K(+G)4b-plasmid complexes show 
differences in their height to volume ratio.  In the phase imaging, the large structures 




packed together.  Previous results demonstrate H3K(+G)4b better coats plasmid DNA 
providing better protection and charge neutralization at lower concentrations.  The 
greater extent of charge neutralization for H3K(+G)4b peptide may result in the larger 
particles observed, consisting of smaller ones aggregated together.  The other 
possibility is that H3K(+G)4b does not form overcharge regions of aggregated 
peptide, therefore we can observe individual demarcations inside large complexes.  
The DLS data also demonstrates that H3K(+G)4b forms an aggregating structure that 
gets larger over a 22 minute time period.  H3K(+G)4b’s complex formation has a 
larger height to diameter ratio that could be an indication a more stable structural 
formation.  H3K(+G)4b’s better transfection of plasmid DNA could be due to greater 
structural stability.  DNA complexes formed with H3K4b also demonstrate 
aggregation of individual particles, but to a lesser extent.  DLS results confirm that 
H3K4b complex form smaller structures.  Overall the morphologies of H3K4b and 
H3K(+G)4b present some subtle differences that are in agreement with differences in 
packaging observed in other experiments. 
A large difference is observed between the morphologies of H3K4b and 
H3K(+G)4b complexes with siRNA.  H3K4b has a much larger height to diameter 
ratio than H3K(+G)4b, suggesting a more ridged structure.  H3K4b transfects siRNA 
better than H3K(+G)4b, perhaps due to a more rigid structure that protects siRNA 
























5.1 Model for H3K4b and H3K(+G)4b Binding to Plasmid DNA 
The data on H3K4b and H3K(+G)4b binding interactions with nucleic acid 
lead to a model for the complex formation.  Each piece of data gathered, as it stands 
alone, presents a supportive piece of evidence for how both peptides complex with 
nucleic acid.  However, when pieced together, these data provide a very strong body 
of evidence for the mode of action of each of these peptides.  This model reflects the 
key differences observed for H3K4b compared to H3K(+G)4b in transfection 
efficiency, the DNase I degradation, fluorescence dye exclusion experiments, DLS, 
AFM, and ITC.  Both the DNase I and EtBr exclusion experimental models have been 
used as the basis for the overall mechanistic model for peptide-nucleic acid complex 
formation.  This overall model is presented in Figure 5.1 for H3K4b and H3K(+G)4b 
binding to plasmid.  The key observations of each experiment were put into context 
with one another to explain how this model was formulated. 
For H3K4b, the EtBr experiments revealed that more peptide was required to 
reach the same extent of EtBr exclusion as H3K(+G)4b.  However we also observed 
that H3K4b reached a greater extent of EtBr exclusion than H3K(+G)4b at saturating 
concentrations of peptide.  How can the differences observed here be reconciled?  
What is believed to occur is that H3K4b, not having the added glycines in each 
branched region, has more steric hindrance and is not as flexible as H3K(+G)4b.  As 
seen in Figure 5.1, upon initial addition and binding of H3K4b below a 3 N/P (1:1 
charge:charge) ratio, there is incomplete coating of plasmid DNA due to peptide 
inflexibility.  Part of the incomplete coating observed could be due to the fact H3K4b 








Figure 5.1 Coating Versus Clumping Mechanism for H3K4b and H3K(+G)4b Complex Formation 
with Plasmid DNA.  Only a section of plasmid DNA binding for both peptides is shown initially in 
order to illustrate binding on an individual peptide scale.  Starting at the top, H3K4b or 
H3K(+G)4b peptide is added to plasmid DNA.  Peptide binding at lower concentration occurs 
through some hydrogen bonding and electrostatic interaction with the DNA.  Small amounts of 
peptide binding will not yield change in DNA compaction because very little charge 
neutralization has occurred.  As more peptide is added and a 1:1 charge neutralization ratio of 
peptide to DNA is reached, DNA will start to compact and the complex will begin to aggregate.  
The starred bracket denotes one single step that is comprised of two simultaneous intermediates.  
Binding of peptide and compaction of plasmid occur simultaneously once charge neutralization 
is approached.  H3K4b (blue) incompletely coats the plasmid DNA, leaving gaps of naked DNA 
during complex formation.  Condensation of plasmid DNA with H3K4b occurs with pockets of 
peptide and plasmid DNA clumping together.  This can lead to overcharged regions of clumped 
peptide.  Upon aggregation, H3K4b forms a less densely packed aggregate that has regions of 
clumped peptide and exposed DNA on the surface.  H3K(+G)4b coats plasmid DNA more evenly 
due to the increased flexibility of the added glycines, which leads to less exposed regions of 
plasmid DNA.  During condensation, H3K(+G)4b folds the DNA leading to better charge 
neutralization and compaction of DNA, forming a densely packed aggregate. 
of excess charge in the complex.  Upon addition of more peptide and at saturating 
concentrations of H3K4b, the peptide fills in some of the naked regions of plasmid 
DNA, demonstrated by its greater exclusion of EtBr.  However, even at the 3.6 N/P 
ratio, H3K4b never reaches complete coating of the plasmid. The evidence of 
H3K4bs lesser ability to coat plasmid than H3K(+G)4b was unclear from the EtBr 
exclusion assay alone because H3K4b ended up excluding more EtBr at saturating 
concentrations.  The DNase I degradation experiment, conducted at a range of N/P 
ratios corresponding to those of the EtBr experiment, proved that there are exposed 
regions of plasmid which H3K4b does not protect.  The reason these exposed regions 
of plasmid exist could be due to overly positively charged regions of H3K4b-plasmid 
complex makings these regions of plasmid inaccessibility to additional positively 
charged peptide.  Zeta potential measurements would tend to corroborate this because 
other HK peptide complexes have proved to be positively charged in the past, 
indicating an excess of positive charge44.  The binding of a 1:1 charge to charge ratio 
of peptide to DNA is a combination of two simultaneous intermediates, H3K4b 




demonstrated initial enthalpically driven binding of the peptide to the DNA, followed 
by an entropically driven reaction, which is due to electrostatic interaction driven by 
release of counterions and water into solution.  Locally condensed regions of 
overcharged peptide and plasmid DNA are presumed to resemble “beads on a string”, 
in which there are protected “beads” of peptide-plasmid complex, with exposed 
“string” regions of naked plasmid in between.  Evidence for the “beads on a string” 
have come from single molecule pulling experiments conducted by Dr. Joonil Seog’s 
lab at the University of Maryland, Department of Material Science and Engineering 
(unpublished data).  These experiments have observed how much force it takes to pull 
apart a complex formed with a single piece of DNA that has peptide bound to it. 
The final part of the electrostatic interaction between H3K4b and DNA 
binding is aggregation of the overcharged regions of particles formed.  DLS and AFM 
results corroborate condensation of peptide-plasmid complexes.  The ITC data for 
H3K4b complex formation demonstrates a higher enthalpy of formation, possibly 
between overcharged regions of the complex.  DLS results for H3K4b-plasmid 
complexes revealed a smaller size than those made with H3K(+G)4b.  The smaller 
size observed might be due to a less stable structural formation for the aggregate.  The 
final phase of H3K4b binding includes the aggregation of multiple peptide-DNA 
complexes together.  From DLS and AFM results we know the 300 nM particle size 
for a complex is composed of many individual complexes aggregated together.  As 
indicated by AFM results, complexes formed with H3K4b tend to be smaller and 
have a lower height to diameter ratio.  Clumped “beaded” regions of peptide on the 




The results for H3K4b-DNA complex formation suggest that it is a less stable 
complex, which has a greater susceptibility to nuclease degradation making it less 
effective for plasmid transfection. 
H3K(+G)4b is believe to be have less steric hindrance than H3K4b due to the 
added glycines interspersed in between the beginning and middle of each of the four 
branched regions.  The EtBr exclusion assay suggests that H3K(+G)4b in complex 
with plasmid reaches its full extent of EtBr exclusion at a lower N/P ratio close to 1.8 
compared to H3K4b.  Full extent of EtBr exclusion at lower N/P ratios indicates 
H3K(+G)4b’s effectiveness at coating and excluding EtBr at lower concentrations  
suggesting that more lysines can interact with the DNA.  Upon reaching a 1:1 charge 
ratio the peptide has even distributed on the plasmid DNA completely covering it.  At 
saturating concentrations more peptide binds and excludes slightly more EtBr, 
however, the full extent of EtBr exclusion has mostly (90%) been reached by this 
point.  DNase I results strongly corroborated this theory, demonstrating complete 
protection of plasmid DNA by H3K(+G)4b at a 3.6/1 N/P ratio.  As H3K(+G)4b 
binds there is also a condensation event in which compaction of the peptide-plasmid 
complex occurs.  Because of the even coating of H3K(+G)4b, there is tighter 
compaction of the condensed complex formed, with little to no naked regions of 
plasmid DNA.  DLS demonstrates better charge neutralization for an H3K(+G)4b 
complex because it forms a larger complex than H3K4b, indicating less charge 
repulsion between complexes due to complete coverage.  These charge neutralized 
complexes come together to form a larger aggregated particle of DNA and peptide.  




which demonstrates H3K(+G)4b’s larger size.  Demarcations inside large complexes 
can also be observed from the AFM results, presenting that aggregates of peptide and 
plasmid are comprised of many complexes.  The experimental evidence demonstrate 
H3K(+G)4b contributes to formation of a well-coated and compact plasmid-peptide 
complex, which is very stable during serum transport.  The enhanced stability of 
H3K(+G)4b-plasmid complex formation makes it a good transfection agent of 
plasmid. 
Overall, the data gathered for siRNA binding did not lead to a conclusive 
model of peptide binding that describe the difference in siRNA transfection 
efficiencies presenting H3K4b as more effective than H3K(+G)4b.  From the 
proposed model of H3K4b and H3K(+G)4b binding to plasmid DNA, we can 
speculate as to what aspects of peptide-siRNA complex formation cause the observed 
difference in transfection efficiencies.  We submit that those properties that make 
H3K4b an ineffective agent of delivery for plasmid, makes it effective for shorter 
nucleic acids like siRNAs.  It is believed that H3K4b forms more clumped and 
aggregate regions during complex formation with plasmid.  These clumped “bead 
regions” of peptide are highly positively charged and make it difficult for additional 
peptides to fill in unprotected regions of the plasmid.  However, in the case of siRNA 
this clumping may be much more effective for delivery.  The siRNA being only 21 bp 
in length is significantly shorter than the plasmid and has a very rigid structure80.  
Plasmid DNA, being much larger, flexible and having a complex topology, would 
have to rely on effective coating and compaction for delivery.  In the case of the 




however, no folding of the nucleic acid is needed for protection.  The final complex 
formed could be similar to that of a dendrimeric one where there is a cage that forms 
around the siRNA and protects it35.  This way the small, stiff siRNA molecules are 
imbedded inside an aggregate of H3K4b that is formed by the charge neutralization 
occurring between the nucleic acid and peptide.  We know from the DLS results that 
complexes formed with siRNA and H3K4b are larger than those of H3K(+G)4b 
indicating better charge neutralization and aggregation.  The AFM matches the DLS 
results, which present H3K4b-siRNA particles with a larger height to diameter ratio.   
The observations made about H3K(+G)4b binding to plasmid DNA describe 
why it is completely ineffective for siRNA delivery.  H3K(+G)4b may have more 
flexibility allowing for better coating of plasmid, which may not be a desired attribute 
for small siRNA complex formation and delivery.  The enhanced flexibility may not 
provide the structural support needed to form a stable complex.  We know from AFM 
and DLS results, H3K(+G)4b-siRNA complexes are less uniform and have a smaller 
height to diameter ratio.  In addition, H3K(+G)4b may actually be coating the siRNA 
better than H3K4b.  The problem with effective coating may be that binding is too 
tight and the siRNA may not be getting released from the complex to its target.  
These factors contribute to H3K(+G)4b ineffectiveness at delivery of siRNA.   
5.2 Implications of Improved Transport afforded by H3K4b and H3K(+G)4b in 
Serum 
 The biological relevance of characterizing of H3K4b and H3K(+G)4b is of 
paramount importance.  A connection has to be made between characterization of 




towards creation of better delivery agents.  Out of all of the factors for effective 
deliver, only two major aspects in formation of the complex are of immediate 
importance to delivery.  One of those is transport of the nucleic acid during delivery.  
Three factors are important when considering travel of the complex to its target: 
condensation, protection and localized delivery of the nucleic acid.  Condensation of 
nucleic acids is the simplest, yet most important factor in transport and stability of the 
nucleic acid complex.  Without charge neutralization and condensation of nucleic 
acids, they will never be able to enter the cell to effect therapy.  Naked nucleic acids 
have a high negative charge density and large size, which will make it difficult to 
penetrate cellular membranes40; 81.  In the case of larger nucleic acids like plasmid 
DNA, condensation is crucial for delivery.  Polycationic packing agents have been 
proven to be effective in protection and delivery of small (about 20 base pair) 
siRNAs40.  However a, 3 kb plasmid is much larger and will have a more complicated 
condensation interaction with a polycationic packaging peptide.  Compaction of 
plasmid DNA as a key aspect to delivery is clearly related to the DLS results obtained 
in this study.  H3K(+G)4b peptides ability to condense DNA into a neutrally charged 
particle was demonstrated by the presence of a larger complex compared to H3K4b.  
In addition, increase in the size of the plasmid-H3K(+G)4b complex was 
demonstrated over a 20 minute time period, indicating aggregation of charge 
neutralized complex.  The H3K(+G)4b peptides reduced steric hindrance may be 
responsible for its better condensation of plasmid DNA.  DLS results demonstrated 




condensation and charge neutralization.  Once condensed effectively, these 
complexes can undergo endocytosis to be taken in by the cell40. 
Exposure to a vast variety of biological media during the transport process of 
a packaged complex presents major hurdles in preventing degradation of siRNA or 
plasmid.  This major difficulty must be overcome in order to keep the nucleic acid 
intact during transport.  Nucleic acids by themselves, especially siRNA, prove to be 
very unstable during transport through biological serum due to the presence of 
nucleases39; 40; 82.  Merkel conducted a series of assays that used PEI as a delivery 
agent for siRNA in which the lungs were targeted82.  His experiments address critical 
aspects for protection of a nucleic acid during transport of a complex formed with a 
polycationic delivery agent.  Survivability of the PEI-siRNA complex proved to be 
enhanced in two biological media, mucin and lung surfactant, which are 
representative of conditions found at mucus membranes and the environment in the 
lungs82.  Exposure of nucleic acids to biological systems during therapeutic delivery, 
especially mucus membranes, will be an important barrier to consider during 
delivery.  Upon incubation of PEI-siRNA complexes in mucin and lung surfactant, 
enhanced stability and survivability was observed for these complexes82.  Other 
experiments have also shown direct protection of siRNA and plasmid DNA from 
degradation by nucleases.  PEI in complex with siRNA has proven to protect against 
degradation by RNase A40.  Assays have also been conducted looking at DNase I 
degradation of plasmid DNA in complex with nanoparticles and block-copolymer 
condensing agents39; 45.  DNase I and RNase A experiments conducted by other labs 




protect plasmid DNA39; 40; 45.  Again H3K(+G)4b increased flexibility lends itself to 
better coating of plasmid, better protecting it.  H3K4b was not completely effective at 
protection of plasmid and provided protection from DNase I only at an N/P of 4.8.  
The evidence provided here proves the utility of polycationic agents in increasing 
stability of siRNA in biological fluids. 
Linked to protection is also diffusion of nucleic acid delivery complexes once 
they are introduced into a biological media.  In order for delivery to be effective, the 
complex must localize nucleic acid release to a desired target region.  Naked siRNA 
shows rapid dispersal and excretion upon introduction to serum82.  Nucleic acids like 
siRNA are particularly prone to rapid accumulation in the liver and kidneys leading to 
excretion.  Polycationic polymers like PEI have been shown to improve survivability 
and localization of delivered siRNA over that of naked siRNA82.  Another experiment 
by Merkel observed localized targeting of the PEI-siRNA complex to the lungs82.  
Twenty-four hours after exposure of the PEI-siRNA complex, a significant amount of 
PEI-siRNA complex was still found in the lungs where it was initially introduced82.  
In this case, PEI proved to be effective at keeping the siRNA release localized to 
where it was targeted.  Much of the survivability and localized targeting also has to 
deal with controlled release of the nucleic acids of interest.  H3K4b and H3K(+G)4b 
both demonstrate effective binding to nucleic acid as demonstrated by the EtBr 
exclusion assays.  This effective binding may provide localized delivery of nucleic 
acid in a biological environment.  As demonstrated in DLS, complexes that are 
aggregated will be a combination of hundreds of nucleic acids and thousands of 




advantage of H3K4b and H3K(+G)4b in localized delivery is that they can be 
modified during their synthesis.  These modifications could include molecules and 
functional groups that are targeted to specific cells or tissues. 
The biological significance of condensation, protection and localized delivery 
of a nucleic acid are critical factors when considering polycationic packaging vectors 
development. 
5.3 Effect of a Peptide Complex Formed on Endosomal Release 
 Effective transport is only one major factor for effective delivery of a 
therapeutic nucleic acid.  The other factor that influences nucleic acid delivery is once 
safely transported to its destination, it must be released to its target.  The major route 
of entry for a nucleic acid-catoinic polymer complex is typically some form of 
endocytosis.  There are a few major types of endocytosis, but all involve a similar 
principle83.  An invagination of the cells plasma membrane occurs at the site of the 
particle taken in.  This invagination then encompasses the particles and brings it 
inside the cell.  The endosome containing the nucleic acid-polymer complex is then 
pinched off from the plasma membrane to be internalized into the cell and has many 
fates as illustrated in Figure 1.3.  The one important fate of the endosome to mention 
here is fusion with a lysosome84.  The lysosome contains many catalytic and 
degradative elements, which have a large impact on the contents of the endosome84.  
Delivery complexes can be extremely sensitive to the pH of the endosomal and 
lysosomal vesicles interior compartment.  A typical endosome has a size of around a 
couple hundred nm in diameter.  The average lysosome is about 500 nm in 




ions will have a large impact on the internal environment.  The vesicles sensitivity to 
pH change is the major proposed mechanisms for release of nucleic acid-polymer 
complexes into the cytosol. 
At physiological pH the average charge of the H3K4b and H3K(+G)4b 
peptides is +24, which includes only the lysines because they are the only species 
protonated.  The histidines are not protonated at physiological pH because it is a full 
pH unit above their pKa.  Protons are pumped into the endosome from the cytosol by 
an ATPase enzyme11.  The endosomal pH drops to about 5 when pinched off from the 
cell membrane.  In this endosomal environment, it is estimated that up to 40% of 
amines can be protonated, in the case of PEI36.  If all of the histidines were protonated 
on the H3K4b and H3K(+G)4b peptide, this would increase the charge to +72.  This 
has a major effect on the charge of the very small internal space of the endosome.  To 
counteract this increase in charge, the endosome takes in chloride ions and also water 
to balance the increase ion concentration36.  This sudden influx of positive ions, 
negative ions and water causes swelling and destabilization of the endosome36.  This 
in turn can lead to rupture of the endosome and release of its contents into the 
cytosol36.  This mechanism of rupturing the endosome through a sudden influx of ions 
has been termed the proton sponge hypothesis, which has been mentioned briefly in 
the introduction (Figure 1.4).  This theory has backing by theoretical models and 
experimental evidence36; 85.  The primary role of the histidines in the H3K4b and 
H3K(+G)4b is release of the nucleic acid-peptide complex through this mechanism.   
When considering the proton sponge mechanism it is important to note that 




endosome.  Release of the complex from the endosome is important to delivery of the 
nucleic acid to the cell, however, once inside the cytosol the nucleic acid has to also 
be released from the peptide.  There has been a case where a delivery agent bound to 
the nucleic acid too tightly, and does not allow its release for effective therapy82.  
Tightness of complex formation is a sensitive balance between adequately protecting 
the nucleic acid during transport and allowing a weak enough binding interaction to 
allow dissociation of the agent from the nucleic acid.  Once the nucleic acid-peptide 
complex dissociates, plasmid DNA can be taken up by the nucleus to effect gene 
delivery or in the case of siRNA for RNAi, released into the cytosol.  The large 
change in pH experienced by the complex during endosomal rupture can be 
speculated to play an important role in release of the nucleic acid from the peptide.  
Inside the endosome, at pH 5, the histidines on the peptide will be highly positively 
charged and may facilitate in tighter binding of the peptide to the nucleic acid.  
However, once ruptured, the complex will experience a large increase of the pH to 
about 7.5, causing a significant loss in the positive charge of the peptide.  Similar to 
endosomal rupture, this drastic deprotonation of the peptide due to change in the pH 
could cause a destabilization in the interaction between the peptide and nucleic acid.  
The destabilized complex then falls apart, releasing a large majority of the nucleic 
acid bound up in it.   
 One more factor that could be aiding in release of H3K4b and H3K(+G)4b 
complexes from the endosome has to do with the PII helical structure observed for 
this peptide.  From the CD analysis of both H3K4b and H3K(+G)4b, in the absence 




peptides in nature, which form an alpha helix that has been shown to disrupt and 
rupture the plasma membrane86.  These antimicrobial peptides work to either disrupt 
the interaction between lipid molecules or create pores (or holes) in the cells 
membrane, which cause it to rupture86.  Since H3K4B and H3K(+G)4b can form a PII 
structure, the helix they form could be causing a similar effect on the membrane of 
the endosome.  PII helicies have demonstrated the ability to interact with cellular 
membranes87; 88.  Excess peptide released from the complex or on its surface could be 
interacting with the plasma membrane, disrupting it and causing it to rupture and 
release the contents. 
 When developing a nucleic acid delivery system, release of the complex from 
the endosome and the delivery agent is important to successful therapy.  Future 
designs of delivery agents will want to take advantage of the successful release of 
nucleic acids afforded by H3K4b and H3K(+G)4b. 
5.4 Concluding Remarks on H3K4b and H3K(+G)4b Contributions to Effective 
Transfection 
The transport and release of nucleic acids are the two crucial components 
needed for effective delivery.  All characterization of H3K4b and H3K(+G)4b have 
been completed with those parameters in mind.  For H3K(+G)4b, flexibility is key to 
protection and delivery of larger nucleic acids such as plasmid.  H3K(+G)4bs ability 
to complex and better aggregate plasmid will be an important consideration for gene 
delivery.  However, this same benefit for packaging plasmid DNA, makes it 
inefficient for delivery of siRNA.  In the case of H3K4b, a stiffer, dendrimer-like 




provide ineffective in delivery and protection of plasmid.  A delicate balance between 
adequate protection and release of nucleic acids must occur for effective delivery.  
Uncovering these characteristics of H3K4b and H3K(+G)4b-nucleic acid complex 
formation are important in creation of future transfection agents.  The model 
developed from our work is a starting point for future models detailing the chemical 
interactions and processes necessary for successful nucleic acid delivery.  H3K4b’s 
and H3K(+G)4b’s current effectiveness as delivery agents will have broad 




Appendix 1: SafteyCoat Procedure and Matlab Code 
1.1: SafteyCoat Procedure For Silicoizing Cuvettes: 
• Reproducibility of initial fluorescence quenching experiments with an alexa 
555 labeled linear HK peptide proved to be very difficult.  Pipetting up and 
down once with a non-siliconized pipette in a cuvette containing a sample of 
peptide with DNA, demonstrated vast differences in the fluorescence signal 
from scan to scan (without any further addition of peptide).  It was determined 
that peptide sticking to the surface and being dislodged upon mixing was the 
cause for the lack of reproducibility.  Siliconization corrected the sticking 
problem. 
• If using glassware that has been previously used or exposed to biomolecules 
or have used sigma coat previously on a surface, clean off the surface.  
Removing dirt or particulates can be accomplished by doing an acid wash 
(concentrated Nitric Acid), which sits for about 1-2 hours or so and followed 
by a rinse with copious amounts of water. 
• Caution: Follow the safety instructions for sigma coat!  Use in a well 
ventilated area and use gloves!  Apply the sigma coat to the piece of glassware 
or just dip the glassware in some of the solution and let it sit for 15 minutes.  
Typically, with a cuvette just fill it with the solution and let it sit for the 15 
minutes. 
• Pour the solution out of the cuvette or remove the piece of glassware from the 




ventilation and the surface area being dried, ect.  If the sigma coat does not 
completely dry, simply remove any excess with a Kimwipe. 
• This treatment should leave a hazy coating on surface of the piece of 
glassware coated which can be removed by polishing with a Kimwipe.  To 
polish the inside of the cuvette, use a small gauge needle, about 23, and wrap 
it with a Kimwipe.  Caution: Be careful that the needle does not poke through 
the Kimwipe and scratch the glass! 
• Finally wash the freshly coated surface using ethanol and then water 
repeatedly to ensure any residue is removed.  The formation of many bubbles 
may occur when using a freshly coated cuvette for the first time.  Repeated 
use and rinsing with water should eventually reduce the amount of bubbles. 
• The siliconization of cuvettes that are heavily used lasts about 3 months.  If a 
cuvette has not been used for 4 months, the Siliconization procedure should be 
repeated.  When the siliconization starts to wear out, fluid stays stuck to the 
cuvette during drying with an air can.  This process should be repeated at 
those time intervals to keep results reproducible. 
 
1.2: Matlab Analysis and Program For CD Spectral Decomposition: 
• Import HK_Minimization.mat into matlab.  This contains the matrices for the 
buffer-subtracted experimental data and reference spectra for the peptide and 
siRNA.  The only thing that needs to be done next is to run 
error_min_search_stoich.m.  This program calls on functions that create all 




nucleic acid complex and the binding stoichiometry.  The two functions that 
need to be present in your workspace to correctly operate the program are 
spec_mat_stoich.m and err_vs_exp_stoich.m.  Here is the code for the 
programs needed to run the minimization: 
 
error_min_search_stoich.m: 
% Script for obtaining optimal reference spectrum and stoichiometry 
%Example 
%run = @(z)((15-z)^2); 
%[x,fval] = fminsearch(run,[1]) 
  
% Assumes x5000uM_HK_buffed, HK_titr_buffed, and siRNA_Avrgdsig are already 
in the workspace 
  
ref_spect_complex = zeros(size(x5000uM_HK_buffed)); 
HK_reference_mat = [(x5000uM_HK_buffed)/(5)  ref_spect_complex  
(siRNA_Avrgdsig)/(0.45)]; %HK originally divided by (5).  siRNA originally divided 
by (0.45) to get 1uM of peptide and siRNA. 
  
  
%numconcs is the total number of concentrations of siRNA relative to a 
%single peptide concentrations (m x n, wavelength x concentations) 
siRNA_HKtitr_Conc_values = [0045' , 0089' , 0130' , 0180' , 0220' , 0260' , 0310' , 
0350' , 0390' , 0430' , 0640' , 0830' , 1030' , 1210' , 1620' , 2030' , 2440' , 2850' , 3260' 
, 3670' , 4080' , 4490']'; 
siRNA_conc_vec = siRNA_HKtitr_Conc_values; 
pep_per_rna = 1; 
pept_init = 5000; 
  
numconcs = size(siRNA_conc_vec,1); 
  
stoich_and_spec = [pep_per_rna ; ref_spect_complex]; 
  




%[stoich_and_spec , fval, exitflag,output] = 
fminsearch(err_norm,stoich_and_spec,fminopts) 






pep_per_rna = stoich_and_spec(1) 
ref_spect_complex = stoich_and_spec(2:end); 
new_HK_reference_mat = HK_reference_mat; 
new_HK_reference_mat(:,2)=ref_spect_complex; 













function [ species_matrix ] = spec_mat_stoich( pept_init, pep_per_rna, 
siRNA_conc_vec  ) 
%UNTITLED2 Summary of this function goes here 
%   Detailed explanation goes here 
% 
%numconcs is the total number of concentrations of siRNA relative to a 
%single peptide concentrations (m x n, wavelength x concentations) 
% 
  
%siRNA_HKtitr_Conc_values = [0045' , 0089' , 0130' , 0180' , 0220' , 0260' , 0310' , 
0350' , 0390' , 0430' , 0640' , 0830' , 1030' , 1210' , 1620' , 2030' , 2440' , 2850' , 3260' 
, 3670' , 4080' , 4490']' 
%siRNA_conc_vec = siRNA_HKtitr_Conc_values; 
%pep_per_rna = 5; 
%pept_init = 5000; 
  
%numconcs = size(siRNA_conc_vec,1) 
% 
% pep_cons requires two approximated inputs: the initial peptide concentration 
spectrum and the stoicheometry of peptide to rna 
% defined above in the function as pep_per_rna (i.e. 4:1 = 4) 
% 
pep_concs = max(pept_init - pep_per_rna*siRNA_conc_vec,0); 
comp_concs = min(pep_per_rna*siRNA_conc_vec,pept_init); 
siRNA_concs = max(0, siRNA_conc_vec - pept_init/pep_per_rna); 








%We first have to define a function that encompasses all of our matrix 
%knowns and variables.  We refer back to this function below in err_norm. 
function err_norm = err_vs_exp_stoich(stoich_and_spec, HK_titr_buffed, 
HK_reference_mat,pept_init,siRNA_conc_vec)  
  
%First we have to define the variable vector we are going to minimize.  We 
%accompish this by defining a new vector, new_HK_reference_mat, that will be our  
%new reference spectra that will include the new mimimalize values for the  
%theoretical combined siRNA and HK ref specs.  We then defined the row that  
%our new values will replace and called it ref_spect_complex, which we definined in  
%the function above.  This set up is what needs to be done inorder to  
%minimize one vector among a know set of data. 
new_HK_reference_mat = HK_reference_mat; 
  
pep_per_rna = stoich_and_spec(1); 
ref_spect_complex = stoich_and_spec(2:end); 
new_HK_reference_mat(:,2)=ref_spect_complex; 
species_mat = spec_mat_stoich(pept_init, pep_per_rna, siRNA_conc_vec); 
  
%Below is the definition for the error of our combined matricies.   
err_mat = (HK_titr_buffed-(new_HK_reference_mat*species_mat));  
  
%err_norm = norm(err_mat*(transpose(err_mat)),'fro');  









Appendix 2: Topologically Constrained Minicircles and Linear 
DNA constructs as Tools for Assaying the TATA Box Binding 
Protein-DNA Interaction 
Overview: 
 The TATA-Box binding protein (TBP) is a unique binding protein that 
interacts with the minor groove of DNA.  Much has been discovered about this 
protein because of its key role in transcriptional initiation.  Because this proteins 
binding interaction relies upon a unique structural topology of DNA, uncovering its 
mechanism of binding can lead to a better understanding of protein-DNA interactions.  
This is a brief introduction on the TBP research conducted and a synopsis of the 
results gathered for assessment of TBP’s binding mechanism using a series of 
different DNA constructs. 
 
Introduction: 
TBP is roughly 180 amino acids long with a size of about 38kDa89; 90.  The 
protein is comprised of two very similar, semi-symmetric domains as seen in Figure 
189; 90.  It’s characterized by a series of beta-sheets which form the hydrophobic 
interface between the protein and the DNA binding region89.  As a part of this 
interface there are a pair of phenylalanine residues that partially intercalate between 
the first two and last two bases of the TATA repeat89.  The series of beta-sheets is 
held in placed by a backbone of four alpha helices89.  The protein is a rigid C-shaped 




bending DNA because it can introduce structural deformation in the TATA box 
essential for transcription initiation.  A key factor in TBPs binding is the fact that it 
binds in the minor of DNA and not the major groove89; 91.  This is a curious and 
 
Figure 1. A pymol cartoon illustration of TBP showing its secondary structural motifs of alpha 
helices and anti-parallel beta sheets.  The four purple space-filling residues are the 
phenylalanines, which partially intercalate between the first and last two base pairs of the 
TATA-box.  
somewhat puzzling aspect of TBPs binding due to the fact that most of the well-
characterized DNA binding proteins, such as the lac repressor, bind in the major 
groove because of the more extensive hydrogen bonding network found there92; 93.  
This is a strong indication that more than just site recognition is guiding TBP 
binding94.  This leads us to inquire as to what are the key characteristics of the DNA, 
which contribute to TBP binding.  In combination with the key structural 
characteristics of TBP, a multitude of unique structural characteristics of the TATA-
Box DNA sequence play a major role in TBP binding and transcription initiation.  
TBP binds to an eight base pair region of DNA characterized by a TATA repeat, 




easier to deform a TA sequence because of the steric interaction of the methyl group 
on the thymine base pairs96.  Upon binding to the minor groove region of the TATA-
Box sequence, TBP induces severe structural deformations of the DNA, which start 
with an 80o bend of the DNA towards the major groove as seen in Figure 289; 91.  
 
Figure 2. Two different views of TBP bound TATA region illustrate bending and heavy 
deformation of DNA upon binding.  The 80o bending of the DNA can clearly be seen here.  The 
widening of the minor groove is shown which stems from TBP’s hydrophobic beta sheet regions 
interaction.  The phenylalanine’s, shown in purple, kink the DNA and cause a redirection of the 
path of DNA through the TBP bound portion.  This has a significant contribution to the topology 
of the DNA, causing it to be slightly writhed upon TBP binding.  
Much of this bending comes from the previously mentioned pair of phenylalanine 
residues partially intercalating between the first two and last two base pairs of the 
TATA-box region.  They also kink the DNA at the ends of the TATA-box , causing 
the entry and exit points of the of the DNA through the binding site to be very 
different.  This 80o bend is accompanied by a significant untwisting of the DNA by 
105o 89; 91.  This leaves the minor groove of the DNA opened up as TBP settles into 
it89.  This opening and deformation of the DNA is key to the initiation of the 
transcription bubble during TBP’s heavy deformation of the TATA region, which 




The overall specificity of TBP recognition of the TATA sequence does not 
come from typical major groove site recognition or hydrogen bonding recognition, 
but from the inherent structural aspects afforded by the TATA-box region91; 98.  The 
TATA DNA regions great inherent flexibility leads to a more easily deformable 
DNA, which is key in TBP’s recognition and binding to this sequence91.  This is a 
strong indication, as pointed out by some very recent papers, that TBP doesn’t 
necessarily have to bind to the exact TATAWAWR region of DNA but a sequence 
containing TATA-like elements95.  In general, there is a push towards observing the 
importance of different structural features of a DNA sequences and the role it plays in 
initiator recognition99.  Regardless, the necessary structural features of the TATA 
DNA play the major role in TBP binding and recognition and not the exact sequence.  
This makes clear that the path to understanding the TBP TATA region binding 
interaction will be in assessing aspects of TBP binding to different DNA 
conformational motifs.   
A multitude of studies have focused on altering the TATA-box region and 
observing its subsequent effect on TBP binding and TATA DNA bending.  Starr 
initiated work illustrating that content of the 8 base pair TATA region was critical in 
bending angle of this region98.  During this work it was also revealed that the TATA 
region is inherently bent in the opposite direction of the TBP induced bend98.  Parvin 
was among the first to use a circular DNA construct to add to these observations and 
show a TATA-box sequence pre-bent towards the major groove has preferential TBP 
binding100.  These were some of the first indications that the TATA-box regions 




research conducted later by Davis and Kahn that was comprehensive in proving this.   
The two major observation made during their research was that the TATA-box region 
was extremely flexible and that TBP binding induced unexpected topological 
changes.  To further probe the unique dependence on DNA topology for TBP 
binding, Jung and Kahn used a DNA minicircle construct.  Using phenylalanine 
deleted TBP mutants, a series of experiments were conducted to observe the effect of 
the phenylalanines on binding to linear and minicircle DNA.  Their findings proved 
that the phenylalanine mutant TBP binds preferentially not only to minicircle as 
opposed to linear DNA, but to a slightly negatively supercoiled minicircle DNA101.  
The speculated reason for this lies in the phenylalanines partial intercalation in the 
TATA-box sequence.  During the TBP binding process, the phenylalanines play a 
major role in bending the DNA and kinking it at the sites of intercalation89.  The 
result is a very different DNA strand entry and exit angle through the TATA-box 
region yielding a writhed region of DNA.  The only caveat with this writhed segment 
of DNA is the fact that the entry and exit strands will be attached to a chromosome 
and 
 
Figure 3. Flattening of the writhed TATA region of DNA, caused by the partial intercalation of a 
pair of phenylalanines in the start and end of the sequence.  A-F, A being most writhed with no 
phenylalanine retraction and F being completely retracted leading to a flattened DNA, show a 
series of subsequent flattening angles accomplished through step-wise removal of the 




locked into place in-vivo, creating an unfavorable writhed DNA topology in a very 
short piece of DNA.  One plausible description proposed by Kahn in 2000 for how 
TBP deals with this unfavorable DNA topology is through retraction of these 
phenylalanines from between the DNA in the TATA region102 (Figure 3).  Upon 
subsequently different degrees of retraction the TBP could allow for flattening of the 
kinked region of DNA allowing the phenylalanines to accommodate for changes in 
the DNA topology102.  These major discoveries of the TBP binding process gives our 
current proposed view on 
 
Figure 4. A Proposed mechanism for TBP binding to the TATA-Box region of DNA. 
the TBP binding mechanism.  The proposed mechanism is outlined as follows (Figure 
4): 
Initial DNA state: 
o TBP recognizes a transiently flexible state of the TATA-Box region.  
This transiently flexed state is enhanced by its bent topology around a 
histone core91; 100. 
o TBP recognizes this state and binds to the slightly open DNA.  As 
mentioned this open DNA comes from the bent conformation.  The 
TATA repeat is ideal for deformation103. 




o The TBP loosely binds to the TATA region upon recognition of the 
transiently flexed DNA state.  No deformation of the DNA has 
occurred yet91.   
o Phenylalanines of TBP partially intercalate into the first two and last 
two base pairs of the TATA sequence, kinking and making the two 
DNA ends 90 degrees perpendicular to one another103. 
• Second intermediate of DNA deformation upon TBP binding: 
o TBP’s significant deformation and bending of the DNA is the major 
driving force for its tight binding.  There is a lot of energy put into the 
system in order to bend the DNA, therefore it’s not favorable for the 
reaction to go backward91; 104.   
o Upon binding, the hydrophobic backbone of the TBP recognizes the 
minor groove of the DNA.  This backbone interaction is seen (at every 
AA and nucleotide interaction) over the 8 base pairs of the binding 
site, unwinding the DNA in the minor groove.  This in-turn widens (to 
the extent of flattening) the minor groove.  Widening the DNA and 
breaking base pair interactions requires a lot of energy103; 104. 
o Completion of binding and bending of the DNA takes place as TBP 
settles into place.  Final exclusion of water from between the 
hydrophobic interface may take place103; 104. 
o Because there are A-tracts in our construct, it takes longer for the TBP 
to bind to our minicircle.  The bend induced by the A-tracts locks the 




going to take energy.  Once TBP binds it is difficult to break the 
interaction with minicircle DNA because of the energy required. 
o This backbone interaction also bends the DNA 80 degrees towards the 
Major groove104. 
• Final TBP Bound DNA State: 
o TBP uses the phenyalanines to control DNA topology while bound.  
This relieves strain that may be trapped in the DNA upon binding of 
the TBP and TFIID complex102.   
All of the work conducted currently on TBP has given a relatively 
comprehensive analysis of it’s binding mechanism.  This leaves us with a few, very 
focused questioned left to answer about TBP’s binding.  Many experiments to date 
have dealt with altering the TATA-box sequence and observing the effects on TBP 
binding, utilization of some sort of cyclization assay or using short linear fragments 
of DNA to assess binding91; 105; 106.  Very little work has been accomplished utilizing 
a circular DNA construct to observe TBP’s binding since Parvin100.  Jung (2005) 
explored this interaction to a limited extent, however, mainly focusing on how TBP 
phenylalanine deletion mutants bind to a TATA-box containing minicircle.  We set 
out to answer three major questions about TBP binding.  First, since there was a 
difference in binding of TBP between linear and minicircle DNA, what aspects of 
bent DNA topology promote TBP binding?  Secondly, if we provide TBP with a very 
constrained (below one persistence length of DNA) minicircle DNA construct, how 
will this affect binding?  Lastly, how exactly does phenylalanine retraction fit into the 




Inspired by work from Kahn, Parvin, Davis and Jung, we set out to further 
probe the interaction of TBP using different DNA constructs.  By exploiting TBP’s 
sensitivity of binding to different DNA conformations we can probe this interaction to 
a greater extent.  We employed the use of a tightly constrained 106bp DNA 
minicircle with and without A-tracts, a 106bp linear DNA construct and a short 25bp 
DNA construct containing the TATA-box region.  TBP’s unique binding mechanism 
can be assessed by observing its binding to these different DNA molecules.   
 
Results: Study of TBP’s bindings interaction with a 106 base pair A-tract 
minicircle, no A-Tract containing minicircle, 106 base pair linear DNA 
and 25 base pair linear DNA: 
 
The Rationale for using a 106 base pair DNA A-tract minicircle and no A-tract 
minicircle to assess TBP binding: 
The 106 base pair DNA A-tract minicircle (106 A-tM) was chosen to assess the TBP 
binding mechanism because of its key topological characteristics.  The 106 A-tM is 
below one persistence length of DNA, which makes it highly strained and the 
smallest minicircle used to probe the TBP binding interaction.  In using such a small 
minicircle, we are emulating a topologically strained environment reminiscent of 
DNA bound up in chromatin107.  The A-tracts in this minicircle lock the TATA-box 




binds, it will be more difficult for it to open up and bend the DNA.  However, once 
TBP deforms the DNA and fully binds, it will be very difficult to remove.  The 
presentation of the TATA-Box region in the 106 A-tM is ideal for TBP binding. 
The idea behind the no A-tract minicircle 106 NA-tM is that there will be free 
rotation about the DNA helical axis.  During TBP’s binding process, it will be easier 
to open up and bend the DNA because the ends of the DNA will not be locked like in 
the 106 A-tM.  The overall result would be better binding of the TBP but not as long 
lasting.  Since there was less energy put into opening and reorienting the 106 NA-tM, 





Creation of the106 A-tM: 
 
A series of restriction digestion reactions were conducted on the 106 A-tM to 
confirm its creation.  Hind III, Xba I and DNase I digests were performed on the 
construct.  After digestion, a urea denaturing gel and native gel were run.  A trend in 
DNA band movement, in which they move progressively slower, is seen during each 
ligation reaction in the creation process.  The progression in band retardation goes 
from 106 base pair single stranded linear fragment (106 SSL) to the 106 base pair 
single stranded product (106 SSC) and finally a shift to the 106 A-tM.  Our 106 SSL 
runs fastest on the gel and is used as the initial reference point for our shift 
progression.  Hind III and Xba I digestions of the 106 A-tM both show a return of the 
106 SSL band on a denaturing gel.  The control lanes for the 106 SSC and the 106 A-
tM both show some residual 106 SSL and 106 SSC bands, respectively.  This is most 
likely due to either incomplete ligation of the 106 SSC or nicking of the 106 A-tM.  A 




conducted and run on a native gel this time.  This time we see a distribution of the 
three species in each of the digestion reactions.  The goal we successfully 
accomplished was to ensure that a small amount of cleavage enzyme could be used on 
a native gel to reconstitute all of the products used to create the A-tM. 
 





TBP bound 106 A-tM dissociation constant (Kd) EMSA:  TBP binds relatively tightly 
to 106 A-tM.  TBP binding saturates between 20-50nM TBP, which suggests a Kd 
around 30nM. 
 
On and Off-Rates for TBP bound to the 106 A-tM.  For the On-rate, a time 
course of TBP bound to 106 At-M was conducted from 0-55 minutes to assess the 
kinetics of this binding interaction.  The On-rate for TBP shows a rapid binding that 
saturates within the first 2-5 minutes.  This suggests that the initial part of the binding 
mechanism of TBP is fast .  During the Off-rate, TBP was allowed to incubate with 
the 106 A-tM then cold competitor DNA was added over a course of 0-55 minutes to 
observe the disappearance of the bound population.  The Off-rate for TBP binding 
illustrates almost no decrease in the bound population once formed.  This analysis 
proves that once TBP is bound to our construct, it’s difficult to become unbound. 
 






Many attempts to obtain a TBP bound 106 DSL population proved to be 
unsuccessful.  Most of what was observed is a population of DNA molecules, at very 
high TBP concentration that is trapped in the gel well.  This could be due to 
molecules that get hooked together once bound by TBP due to the A-tract region in 
the DNA.  The reason that TBP may have difficulty binding to 106 DSL could be that 
the ends of the DNA are not attached to anything in the 106 DSL, which is not an 
accurate representation of the in-vivo environment.  TBP would normally be bound to 
a bent piece of DNA constrained by chromatin97.  TBP may have a more difficult 
time opening up the DNA and binding if the arms of the DNA are free in solution. 
TBP was added to a short 25mer containing the TATA-box binding region to 
see if the protein would bind to a short piece of linear DNA.  At high concentrations 
of TBP (150-500nM) a bound population was seen to emerge.  The evidence provided 
for TBP’s preferential binding to a short piece of linear DNA compared to a longer 
one indicates that the length of the DNA free ends may have an impact on TBP 





TBP bound 106 A-tM cleavage assays: 
 
Cleavage of a 106 A-tM was conducted with TBP bound.  Isolating a TBP bound 
106 DSL DNA population had proven to be relatively unsuccessful.  In an attempt to 
capture a TBP bound linear population, TBP was allowed to incubate with the 106 A-
tM and then Hind III was added to the reaction for 0-90 minutes.  If TPB was still 
bound upon cleavage, a population of bound and free 106 DSL would be seen.  




evidence for a bound population.  The lack of appearance of a TBP bound linear 106 
DSL DNA is another strong indication for the inability of a longer piece of linear 
DNA to provide a favorable conformation for TBP binding. 
 
106 base pair No A-tract Minicircle (NA-tM):  
 
An EMSA was conducted to determine a dissociation constant (Kd) for TBP 
bound 106 NA-tM EMSA.  TBP binding appears to be weaker to the 106 NA-tM than 




due to the intercalated phenylalanines that are accommodating for differences in 
DNA topology.  The two TBP bound DNA populations being observed could be of a 
writhed and flattened minicircle conformation, which was not observed before during 
binding to the 106 A-tM. 
 
An On and Off-Rate assessment was conducted for TBP bounding to the 106 
NA-tM.  Evidence for two bound populations of TBP is seen on both of these gel 
shifts.  The On-rate gel shows a rapidly appearing bound population of 106 NA-tM.  
Binding seems to occur even faster than in the 106 A-tM on rate experiment 
indicating faster initial binding of the complex.  Again for the Off-rate experiment, 
TBP was allowed to incubate with the 106 A-tM.  Subsequently, cold competitor 
DNA was added over a course of 0-55 minutes to observe the disappearance of the 
bound population.  The Off-rate gel shows another dual bound population that begins 
to dissipate between 20-30 minutes of incubation with the competitor DNA.  This is a 






o A topologically constrained minicircle was successfully created with a 
TATA box region to which TBP bound to. 
o TBP binds preferentially to the topologically constrained minicircle 
compared to linear DNA.  The differences between A-tract and linear 
DNA demonstrate the importance of topology for TBP binding to the 
TATA box. 
o Once TBP is bound to the TATA box region it is hard to remove 
through competition.  When the energy is put into deform the DNA 
and bend it, TBP is firmly attached. 
o TBP’s binding to the No A-tract minicircle supports the idea of an 
initial fast intermediate step in binding.  There is also a subsequent 
slower intermediate in opening the DNA, which is important for 
anchoring the protein to the DNA. 
o These constructs present the basis for a topological analysis for a 
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